

(19) World Intellectual Property Organization  
International Bureau



PCT

(43) International Publication Date  
23 February 2006 (23.02.2006)

(10) International Publication Number  
**WO 2006/019498 A2**

(51) International Patent Classification:  
A61F 2/24 (2006.01)

(21) International Application Number:  
PCT/US2005/021914

(22) International Filing Date: 20 June 2005 (20.06.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10/894,433 19 July 2004 (19.07.2004) US

(71) Applicant (for all designated States except US): AMPLE MEDICAL, INC. [US/US]; 1155 Chess Drive, Suite 104, Foster City, CA 94404 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MACOVIAK, John [US/US]; 5412 Thunderbird Lane, La Jolla, CA 92037 (US). CHANG, Robert, T. [US/US]; 3314 Haskins Drive, Belmont, CA 94002 (US). RAHDERT, David, A. [US/US]; 2127 12th Avenue, San Francisco, CA 94116 (US). MACHOLD, Timothy, R. [US/US]; 65 Bernal Avenue, Moss Beach, CA 94038 (US).

(74) Agents: RYAN, Daniel, D. et al.; P.O. Box 26618, Milwaukee, WI 53226-0618 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DEVICES, SYSTEMS, AND METHODS FOR RESHAPING A HEART VALVE ANNULUS

(57) Abstract: Implants or systems of implants apply a selected force vector or a selected combination of force vectors within or across the left atrium, which allow mitral valve leaflets to better coapt. The implants or systems of implants make possible rapid deployment, facile endovascular delivery, and full intra-atrial retrievability. The implants or systems of implants also make use of strong fluoroscopic landmarks.

BEST AVAILABLE COPY

121

- 1 -

DEVICES, SYSTEMS, AND METHODS FOR  
RESHAPING A HEART VALVE ANNULUS

Related Applications

This application is a continuation-in-part of  
5 co-pending United States Patent Application Serial No.  
10/677,104, filed October 1, 2003, and entitled "Devices,  
Systems, and Methods for Reshaping a Heart Valve  
Annulus," which claims the benefit of United States  
Patent Application Serial No. 09/666,617, filed September  
10 20, 2000 and entitled "Heart Valve Annulus Device and  
Methods of Using Same," which is incorporated herein by  
reference. This application also claims the benefit of  
Patent Cooperation Treaty Application Serial No.  
PCT/US02/31376, filed October 1, 2002 and entitled  
15 "Systems and Devices for Heart Valve Treatments," which  
claimed the benefit of United States Provisional Patent  
Application Serial No. 60/326,590, filed October 1, 2001,  
which are incorporated herein by reference. This  
application also claims the benefit of United States  
20 Provisional Application Serial No. 60/429,444, filed  
November 26, 2002, and entitled "Heart Valve Remodeling  
Devices;" United States Provisional Patent Application  
Serial No. 60/429,709, filed November 26, 2002, and  
entitled "Neo-Leaflet Medical Devices;" and United States  
25 Provisional Patent Application Serial No. 60/429,462,

- 2 -

filed November 26, 2002, and entitled "Heart Valve Leaflet Retaining Devices," which are each incorporated herein by reference.

#### Field of the Invention

5           The invention is directed to devices, systems, and methods for improving the function of a heart valve, e.g., in the treatment of mitral valve regurgitation.

#### Background of the Invention

##### **I. The Anatomy of a Healthy Heart**

10           The heart (see Fig. 1) is slightly larger than a clenched fist. It is a double (left and right side), self-adjusting muscular pump, the parts of which work in unison to propel blood to all parts of the body. The right side of the heart receives poorly oxygenated  
15 ("venous") blood from the body from the superior vena cava and inferior vena cava and pumps it through the pulmonary artery to the lungs for oxygenation. The left side receives well-oxygenation ("arterial") blood from the lungs through the pulmonary veins and pumps it into  
20 the aorta for distribution to the body.

          The heart has four chambers, two on each side -- the right and left atria, and the right and left ventricles. The atria are the blood-receiving chambers, which pump blood into the ventricles. The ventricles are the blood-  
25 discharging chambers. A wall composed of fibrous and muscular parts, called the interatrial septum separates the right and left atria (see Figs. 2 to 4). The fibrous interatrial septum is, compared to the more easily shredded muscle tissue of the heart, a more materially  
30 strong tissue structure in its own extent in the heart. An anatomic landmark on the interatrial septum is an oval, thumbprint sized depression called the oval fossa, or fossa ovalis (shown in Figs. 4 and 6), which is a remnant of the oval foramen and its valve in the fetus.  
35 It is free of any vital structures such as valve

- 3 -

structure, blood vessels and conduction pathways. Together with its inherent fibrous structure and surrounding fibrous ridge which makes it identifiable by angiographic techniques, the fossa ovalis is the favored  
5 site for trans-septal diagnostic and therapeutic procedures from the right into the left heart. Before birth, oxygenated blood from the placenta was directed through the oval foramen into the left atrium, and after birth the oval foramen closes.

10 The synchronous pumping actions of the left and right sides of the heart constitute the cardiac cycle. The cycle begins with a period of ventricular relaxation, called ventricular diastole. The cycle ends with a period of ventricular contraction, called ventricular systole.

15 The heart has four valves (see Figs. 2 and 3) that ensure that blood does not flow in the wrong direction during the cardiac cycle; that is, to ensure that the blood does not back flow from the ventricles into the corresponding atria, or back flow from the arteries into  
20 the corresponding ventricles. The valve between the left atrium and the left ventricle is the mitral valve. The valve between the right atrium and the right ventricle is the tricuspid valve. The pulmonary valve is at the opening of the pulmonary artery. The aortic valve is at  
25 the opening of the aorta.

At the beginning of ventricular diastole (i.e., ventricular filling) (see Fig. 2), the aortic and pulmonary valves are closed to prevent back flow from the arteries into the ventricles. Shortly thereafter, the  
30 tricuspid and mitral valves open (as Fig. 2 shows), to allow flow from the atria into the corresponding ventricles. Shortly after ventricular systole (i.e., ventricular emptying) begins, the tricuspid and mitral valves close (see Fig. 3) -- to prevent back flow from  
35 the ventricles into the corresponding atria -- and the



- 4 -

aortic and pulmonary valves open -- to permit discharge of blood into the arteries from the corresponding ventricles.

The opening and closing of heart valves occur  
5 primarily as a result of pressure differences. For example, the opening and closing of the mitral valve occurs as a result of the pressure differences between the left atrium and the left ventricle. During  
10 ventricular diastole, when ventricles are relaxed, the venous return of blood from the pulmonary veins into the left atrium causes the pressure in the atrium to exceed that in the ventricle. As a result, the mitral valve opens, allowing blood to enter the ventricle. As the  
15 ventricle contracts during ventricular systole, the intraventricular pressure rises above the pressure in the atrium and pushes the mitral valve shut.

The mitral and tricuspid valves are defined by fibrous rings of collagen, each called an annulus, which forms a part of the fibrous skeleton of the heart. The  
20 annulus provides attachments for the two cusps or leaflets of the mitral valve (called the anterior and posterior cusps) and the three cusps or leaflets of the tricuspid valve. The leaflets receive chordae tendineae from more than one papillary muscle. In a healthy heart,  
25 these muscles and their tendinous cords support the mitral and tricuspid valves, allowing the leaflets to resist the high pressure developed during contractions (pumping) of the left and right ventricles. Figs. 5 and 6 show the chordae tendineae and papillary muscles in the  
30 left ventricle that support the mitral valve.

As Figs. 2 and 3 show, the anterior portion of the mitral valve annulus is intimate with the non-coronary leaflet of the aortic valve. As Figs. 2 and 3 also show, the mitral valve annulus is also near other critical  
35 heart structures, such as the circumflex branch of the

- 5 -

left coronary artery (which supplies the left atrium, a variable amount of the left ventricle, and in many people the SA node) and the AV node (which, with the SA node, coordinates the cardiac cycle).

5 Also in the vicinity of the posterior mitral valve annulus are the coronary sinus and its tributaries. These vessels drain the areas of the heart supplied by the left coronary artery. The coronary sinus and its tributaries receive approximately 85% of coronary venous blood. The  
10 coronary sinus empties into the posterior of the right atrium, anterior and inferior to the fossa ovalis (see Fig. 4). A tributary of the coronary sinus is called the great cardiac vein, which courses parallel to the majority of the posterior mitral valve annulus, and is  
15 superior to the posterior mitral valve annulus by an average distance of about 9.64 +/- 3.15 mm.

## II. Characteristics and Causes of Mitral Valve Dysfunction

When the left ventricle contracts after filling with  
20 blood from the left atrium, the walls of the ventricle move inward and release some of the tension from the papillary muscle and chords. The blood pushed up against the under-surface of the mitral leaflets causes them to rise toward the annulus plane of the mitral valve. As  
25 they progress toward the annulus, the leading edges of the anterior and posterior leaflet come together forming a seal and closing the valve. In the healthy heart, leaflet coaptation occurs near the plane of the mitral annulus. The blood continues to be pressurized in the  
30 left ventricle until it is ejected into the aorta. Contraction of the papillary muscles is simultaneous with the contraction of the ventricle and serves to keep healthy valve leaflets tightly shut at peak contraction pressures exerted by the ventricle.

35 In a healthy heart (see Figs. 7 and 8), the

- 6 -

dimensions of the mitral valve annulus create an anatomic shape and tension such that the leaflets coapt, forming a tight junction, at peak contraction pressures. Where the leaflets coapt at the opposing medial and lateral sides of the annulus are called the leaflet commissures.

Valve malfunction can result from the chordae tendineae (the chords) becoming stretched, and in some cases tearing. When a chord tears, the result is a leaflet that flails. Also, a normally structured valve may not function properly because of an enlargement of or shape change in the valve annulus. This condition is referred to as a dilation of the annulus and generally results from heart muscle failure. In addition, the valve may be defective at birth or because of an acquired disease.

Regardless of the cause (see Fig. 9), mitral valve dysfunction can occur when the leaflets do not coapt at peak contraction pressures. As Fig. 9 shows, the coaptation line of the two leaflets is not tight at ventricular systole. As a result, an undesired back flow of blood from the left ventricle into the left atrium can occur.

Mitral regurgitation is a condition where, during contraction of the left ventricle, the mitral valve allows blood to flow backwards from the left ventricle into the left atrium. This has two important consequences.

First, blood flowing back into the atrium may cause high atrial pressure and reduce the flow of blood into the left atrium from the lungs. As blood backs up into the pulmonary system, fluid leaks into the lungs and causes pulmonary edema.

Second, the blood volume going to the atrium reduces volume of blood going forward into the aorta causing low cardiac output. Volume overloads the ventricle, as the

- 7 -

excess blood in the atrium over-fills the ventricle during each cardiac cycle.

Mitral regurgitation is measured on a numeric Grade scale of 1+ to 4+ by either contrast ventriculography or  
5 by echocardiographic Doppler assessment. Grade 1+ is trivial regurgitation and has little clinical significance. Grade 2+ shows a jet of reversed flow going halfway back into the left atrium. Grade 3 regurgitation shows filling of the left atrium with reversed flow up to  
10 the pulmonary veins and a contrast injection that clears in three heart beats or less. Grade 4 regurgitation has flow reversal into the pulmonary veins and a contrast injection that does not clear from the atrium in three or fewer heart beats.

15 Mitral regurgitation is categorized into two main types, (i) organic or structural and (ii) functional. Organic mitral regurgitation results from a structurally abnormal valve component that causes a valve leaflet to flail upward and leak during systole. Functional mitral  
20 regurgitation results from annulus dilation due to primary congestive heart failure, the latter of which is itself generally surgically untreatable, and not due to a reversible cause like severe ischemia or primary valvular heart disease.

25 Organic mitral regurgitation is seen when a disruption of the seal occurs at the free leading edge of the leaflet due to a ruptured chord or papillary muscle making the leaflet flail; or if the leaflet tissue is redundant, the valves may prolapse the level at which  
30 coaptation occurs higher into the atrium with further prolapse opening the valve higher in the atrium during ventricular systole.

Functional mitral regurgitation occurs as a result of dilation of heart and mitral annulus secondary to  
35 heart failure, most often as a result of coronary artery

- 8 -

disease or idiopathic dilated cardiomyopathy. Comparing a healthy annulus in Fig. 7 to an unhealthy annulus in Fig. 9, the unhealthy annulus is dilated and, in particular, the anterior-to-posterior distance along the minor axis is increased. As a result, the shape and tension defined by the annulus becomes less oval (see Fig. 7) and more round (see Fig. 9). This condition is called dilation. When the annulus is dilated, the shape and tension conducive for coaptation at peak contraction pressures progressively deteriorate.

The fibrous mitral annulus is attached to the anterior mitral leaflet in one-third of its circumference. The muscular mitral annulus constitutes the remainder of the mitral annulus and is attached to by the posterior mitral leaflet. The anterior fibrous mitral annulus is intimate with the central fibrous body, the two ends of which are called the fibrous trigones. Just posterior to each fibrous trigone is the commissure of which there are two, the anterior and the posterior commissure. The commissure is where the anterior leaflet meets the posterior leaflet at the annulus.

As before described, the central fibrous body is also intimate with the non-coronary leaflet of the aortic valve. The central fibrous body is fairly resistant to elongation during the process of mitral annulus dilation. It has been shown that the great majority of mitral annulus dilation occurs in the posterior two-thirds of the annulus known as the muscular annulus. One could deduce thereby that, as the annulus dilates, the percentage that is attached to the anterior mitral leaflet diminishes.

In functional mitral regurgitation, the dilated annulus causes the leaflets to separate anterior from posterior leaflet at their coaptation points in all phases of the cardiac cycle. Onset of mitral

- 9 -

regurgitation may be acute, or gradual and chronic in either organic or in functional mitral regurgitation.

In dilated cardiomyopathy of ischemic or of idiopathic origin, the mitral annulus can dilate to the point of causing functional mitral regurgitation. It does so in approximately twenty-five percent of patients with congestive heart failure. If subjected to exercise, echocardiography shows the incidence of functional mitral regurgitation in these patients rises to over fifty percent.

Functional mitral regurgitation is a significantly aggravating problem for the dilated heart, as is reflected in the increased mortality of these patients compared to otherwise comparable patients without functional mitral regurgitation. One mechanism by which functional mitral regurgitation aggravates the situation in these patients is through increased volume overload imposed upon the ventricle. Due directly to the leak, there is increased work the heart is required to perform in each cardiac cycle to eject blood antegrade through the aortic valve and retrograde through the mitral valve. The latter is referred to as the regurgitant fraction of left ventricular ejection. This is added to the forward ejection fraction to yield the total ejection fraction. A normal heart has a forward ejection fraction of seventy percent. With functional mitral regurgitation and dilated cardiomyopathy the ejection fraction is typically less than thirty percent. If the regurgitant fraction is half the ejection fraction in the latter group the forward ejection fraction can be as low as fifteen percent.

### III. Prior Treatment Modalities

In the treatment of mitral valve regurgitation, diuretics and/or vasodilators can be used to help reduce the amount of blood flowing back into the left atrium. An intra-aortic balloon counterpulsation device is used if

- 10 -

the condition is not stabilized with medications. For chronic or acute mitral valve regurgitation, surgery to repair or replace the mitral valve is often necessary.

Currently, patient selection criteria for mitral valve surgery are very selective. Patients will ideally have normal ventricular function, general good health, and a predicted lifespan of greater than 3 to 5 years, NYHA Class III or IV symptoms, and at least Grade 3 regurgitation as indications for mitral surgery. Younger patients with less severe symptoms may be indicated for early surgery if mitral repair is anticipated. The most common surgical mitral repair procedure is for organic mitral regurgitation due to a ruptured chord on the middle scallop of the posterior leaflet.

In conventional annuloplasty ring repair, the posterior annulus is reduced along its length with sutures passed through a surgical annuloplasty sewing ring cuff. The goal of such a repair is to bring the posterior mitral leaflet forward toward to the anterior leaflet to better allow coaptation.

Surgical edge-to-edge juncture repairs, which can be performed endovascularly, are also made, in which a mid valve leaflet to mid valve leaflet suture or clip is applied to keep these points of the leaflet held together throughout the cardiac cycle. Edwards Life Sciences Corporation and Evalve Inc. have developed, respectively, a transvascular suture and a clip to grasp and bond the two mitral leaflets in the beating heart.

Grade 3+ or 4+ organic mitral regurgitation may be repaired with such edge-to-edge technologies. This is because, in organic mitral regurgitation, the problem is not the annulus but in the central valve components.

However, functional mitral regurgitation can persist at a high level, even after edge-to-edge repair, particularly in cases of high Grade 3+ and 4+ functional

- 11 -

mitral regurgitation.

In another emerging technology, the coronary sinus is mechanically deformed through endovascular means applied and contained to function solely within the coronary sinus. Early clinical reports in humans report the inability of these endovascular coronary sinus technologies to reshape the mitral annulus.

It is reported that twenty-five percent of the six million Americans who will have congestive heart failure will have functional mitral regurgitation to some degree. This constitutes the 1.5 million people with functional mitral regurgitation. Of these, the idiopathic dilated cardiomyopathy accounts for 600,000 people. Of the remaining 900,000 people with ischemic disease, approximately half have functional mitral regurgitation due solely to dilated annulus.

By interrupting the cycle of progressive functional mitral regurgitation, it has been shown in surgical patients that survival is increased and in fact forward ejection fraction increases in many patients. The problem with surgical therapy is the significant insult it imposes on these chronically ill patients with high morbidity and mortality rates associated with surgical repair.

The need remains for simple, cost-effective, and less invasive devices, systems, and methods for treating dysfunction of a heart valve, e.g., in the treatment of organic and functional mitral valve regurgitation.

#### Summary of the Invention

The invention comprises various aspects, which are separate and distinct but which can be combined for use, if desired.

One aspect of the invention provides devices, systems, and methods for treating a mitral heart valve using an anchor structure that is located within the



- 12 -

great cardiac vein.

In one embodiment, the devices, systems, and methods install the anchor structure within the great cardiac vein adjacent a length comprising at least a portion of a posterior annulus of the mitral valve. The devices, systems, and methods couple a posterior region of an implant to the anchor structure within great cardiac vein and extend the implant across the left atrium, through an interatrial septum, and into a right atrium. The devices, systems, and methods tension the implant and anchor an anterior region of the implant to tissue in or near the right atrium to maintain the tension. The tension applied by the implant can improve septal-to-lateral dimensions of the valve and thereby lead to improved leaflet coaption to ameliorate functional mitral valve regurgitation. In the case of organic mitral valve regurgitation, the tension applied by the implant can serve to stabilize the posterior annulus in the manner of an annuloplasty ring, to resist change in annulus size during the cardiac cycle.

In one embodiment, the anchor structure can also serve to consolidate the great cardiac vein into a unified physical structure along its length. In this arrangement, the tension applied to the implant is uniformly distributed as a force vector to atrial tissue adjacent the posterior mitral valve annulus through the consolidated great cardiac vein. The consolidation of tissue can enhance the beneficial effects of the implant.

In one embodiment, the devices, systems, and methods conjoin the great cardiac vein to the left ventricle in a tissue region between the consolidated great cardiac vein and the left ventricle. In this arrangement, the implant is configured, when placed into tension, to apply a force vector upon the tissue consolidating anchor structure within the great cardiac vein. The force vector can be

- 13 -

upward, inward, or a combination of both. The force vector is directed by the conjoined tissue region to the left ventricle, to relieve tension on the annulus. As before, the beneficial effects achieved can be thereby  
5 further enhanced.

Another aspect of the invention provides devices, systems, and methods for treating a mitral heart valve using an elongated structure sized and configured to be deployed in tension a circumferential path within the  
10 great cardiac vein adjacent a posterior annulus of the mitral valve. The structure includes an end anchoring region sized and configured to extend from the coronary sinus into the right atrium. An anchor couples to the end anchoring region on the interatrial septum in the right  
15 atrium. The tension applied by the implant can improve septal-to-lateral dimensions of the valve and thereby lead to improved leaflet coaption to ameliorate functional mitral valve regurgitation. In the case of organic mitral valve regurgitation, the tension applied  
20 by the implant can serve to stabilize the posterior annulus in the manner of an annuloplasty ring, to resist change in annulus size during the cardiac cycle.

Another aspect of the invention provides devices, systems, and methods for treating a mitral heart valve  
25 using an elongated structure sized and configured to be deployed as a loop at least in part within the great cardiac vein. In this arrangement, the elongated structure includes first and second end anchoring regions. The elongated structure also includes an  
30 intermediate region coupled to the first and second end anchoring regions. Each end anchoring region is sized and configured, in use, to extend into the right atrium, while the intermediate region is sized and configured to extend outside the right atrium in a circumferential path  
35 within the great cardiac vein adjacent a posterior

- 14 -

annulus of the mitral valve. An anchor couples to the first and second end anchoring regions in the right atrium or a vena cava to hold the intermediate region in tension within the great cardiac vein. The tension applied by the implant can improve septal-to-lateral dimensions of the valve and thereby lead to improved leaflet coaption to ameliorate functional mitral valve regurgitation. In the case of organic mitral valve regurgitation, the tension applied by the implant can serve the stabilize the posterior annulus in the manner of an annuloplasty ring, to resist change in annulus size during the cardiac cycle.

Another aspect of the invention provides devices, systems, and methods for placing implants within a heart chamber. A first implant is deployed within a heart vessel adjacent to a heart chamber, and a second implant is deployed within the heart chamber. According to this aspect of the invention, a region of the second implant within the heart chamber is magnetically attracting to a region of the first implant within the heart vessel e.g., so that the region of the second implant can be coupled to the region of the first implant within the heart vessel.

Other features and advantages of the invention shall be apparent based upon the accompanying description, drawings, and claims.

#### Description of the Drawings

Fig. 1 is an anatomic anterior view of a human heart, with portions broken away and in section to view the interior heart chambers and adjacent structures.

Fig. 2 is an anatomic superior view of a section of the human heart showing the tricuspid valve in the right atrium, the mitral valve in the left atrium, and the aortic valve in between, with the tricuspid and mitral valves open and the aortic and pulmonary valves closed

- 15 -

during ventricular diastole (ventricular filling) of the cardiac cycle.

Fig. 3 is an anatomic superior view of a section of the human heart shown in Fig. 2, with the tricuspid and mitral valves closed and the aortic and pulmonary valves opened during ventricular systole (ventricular emptying) of the cardiac cycle.

Fig. 4 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the interior of the heart chambers and association structures, such as the fossa ovalis, coronary sinus, and the great cardiac vein.

Fig. 5 is an anatomic lateral view of a human heart with portions broken away and in section to show the interior of the left ventricle and associated muscle and chord structures coupled to the mitral valve.

Fig. 6 is an anatomic lateral view of a human heart with portions broken away and in section to show the interior of the left ventricle and left atrium and associated muscle and chord structures coupled to the mitral valve.

Fig. 7 is a superior view of a healthy mitral valve, with the leaflets closed and coapting at peak contraction pressures during ventricular systole.

Fig. 8 is an anatomic superior view of a section of the human heart, with the normal mitral valve shown in Fig. 7 closed during ventricular systole (ventricular emptying) of the cardiac cycle.

Fig. 9 is a superior view of a dysfunctional mitral valve, with the leaflets failing to coapt during peak contraction pressures during ventricular systole, leading to mitral regurgitation.

Figs. 10A and 10B are anatomic anterior perspective views of the left and right atriums, with portions broken away and in section to show the presence of an implant

- 16 -

system that includes an inter-atrial bridging element that spans the mitral valve annulus, with a posterior region anchored in the great cardiac vein and an anterior region anchored on the interatrial septum, the inter-atrial bridging element extending in an essentially straight path generally from a mid-region of the annulus.

Fig. 11 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of an implant system that includes an inter-atrial bridging element that spans the mitral valve annulus, with a posterior region anchored in the great cardiac vein and an anterior region anchored on the interatrial septum, the inter-atrial bridging element extending in an essentially straight path generally from a lateral region of the annulus.

Fig. 12 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of an implant system that includes an inter-atrial bridging element that spans the mitral valve annulus, with a posterior region anchored in the great cardiac vein and an anterior region anchored on the interatrial septum, the inter-atrial bridging element extending in an upwardly curved or domed path generally from a lateral region of the annulus.

Fig. 13 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of an implant system that includes an inter-atrial bridging element that spans the mitral valve annulus, with a posterior region anchored in the great cardiac vein and an anterior region anchored on the interatrial septum, the inter-atrial bridging element extending in a downwardly curved path generally from a lateral region of the annulus.

Fig. 14 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and

- 17 -

in section to show the presence of an implant system that includes an inter-atrial bridging element that spans the mitral valve annulus, with a posterior region anchored in the great cardiac vein and an anterior region anchored on the interatrial septum, the inter-atrial bridging element extending in a curvilinear path, bending around a trigone of the annulus generally from a mid-region region of the annulus.

Fig. 15 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of an implant system that includes an inter-atrial bridging element that spans the mitral valve annulus, with a posterior region anchored in the great cardiac vein and an anterior region anchored on the interatrial septum, the inter-atrial bridging element extending in a curvilinear path, bending around a trigone of the annulus generally from a mid-region region of the annulus, as well as elevating in an arch toward the dome of the left atrium.

Fig. 16 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of an implant system that includes an inter-atrial bridging element that spans the mitral valve annulus, with a posterior region anchored in the great cardiac vein and an anterior region anchored on the interatrial septum, the inter-atrial bridging element extending in a curvilinear path, bending around a trigone of the annulus generally from a mid-region region of the annulus, as well as dipping downward toward the plane of the valve.

Fig. 17 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of an implant system that includes two inter-atrial bridging elements that span the mitral valve annulus, each with a posterior region

- 18 -

anchored in the great cardiac vein and an anterior region anchored on the interatrial septum, the inter-atrial bridging elements both extending in generally straight paths from different regions of the annulus.

5 Fig. 18 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of an implant system that includes two inter-atrial bridging elements that span the mitral valve annulus, each with a posterior region  
10 anchored in the great cardiac vein and an anterior region anchored on the interatrial septum, the inter-atrial bridging elements both extending in generally curvilinear paths from adjacent regions of the annulus.

Fig. 19 is an anatomic anterior perspective view of  
15 the left and right atriums, with portions broken away and in section to show the presence of an implant system that includes three inter-atrial bridging elements that span the mitral valve annulus, each with a posterior region anchored in the great cardiac vein and an anterior region  
20 anchored on the interatrial septum, two of the inter-atrial bridging elements extending in generally straight paths from different regions of the annulus, and the third inter-atrial bridging elements extending in a generally curvilinear path toward a trigone of the  
25 annulus.

Fig. 20 is an anatomic superior view of a section of the human heart, showing the presence of a posterior anchor structure within the great cardiac vein, to which a posterior region of an implant as shown in Figs. 10B  
30 and 11 to 19 can be attached during use.

Fig. 21 is an anatomic section view of the posterior anchor structure taken generally along line 21-21 in Fig. 20.

Fig. 22 is an anatomic superior view of a section of  
35 the human heart, showing the presence of a posterior

- 19 -

anchor structure within the great cardiac vein, to which a posterior region of an implant as shown in Fig. 10B is attached as it would be during use.

Fig. 23 is an anatomic section view of the posterior anchor structure and implant taken generally along line 21-21 in Fig. 22.

Figs. 24 to 30 are anatomic views depicting representative catheter-based devices and steps for implanting an implant system of the type shown in Fig. 10B.

Fig. 31 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of an implant system that includes an inter-atrial bridging element that spans the mitral valve annulus, with a posterior region anchored to a tissue consolidating structure in the great cardiac vein, an anterior region anchored high on the interatrial septum, and showing the great cardiac vein conjoined to the left ventricle by bonding means, the inter-atrial bridging element extending in an upwardly curved or domed path generally from a lateral region of the annulus to provide a force vector that includes an upward lifting component and an inward pulling component.

Fig. 32 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of an implant system that includes two inter-atrial bridging elements of the type shown in Fig. 31 in association with a tissue consolidating element in the great cardiac vein and bonding means that conjoins the great cardiac vein to the ventricle.

Fig. 33A is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of an implant system of the type shown in Fig. 32, with the anterior regions of



- 20 -

the three implants anchored high on the interatrial septum, as well as in the superior vena cava and the inferior vena cava.

Fig. 33B is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of an implant system of the type shown in Fig. 31, with the anterior region of the implant extending through pass-through structure in the interatrial septum (without anchoring) for anchoring in the superior vena cava.

Fig. 33C is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of an implant system of the type shown in Fig. 31, except that the inter-atrial bridging element is generally straight, with the anterior region of the implant extending through pass-through structure in the interatrial septum (without anchoring) for anchoring in the inferior vena cava.

Fig. 33D is an anatomic anterior perspective view of the left atrium, with portions broken away and in section to show the presence of an array of magnetic and/or ferromagnetic elements that conjoin the great cardiac vein to the ventricle.

Fig. 34 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of an implant system of the type shown in Fig. 31, used in combination with other devices that are implanted adjacent the mitral valve annulus.

Fig. 35 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of an implant system that forms a circumferential loop that applies force vectors to tissue in the region of the posterior mitral valve annulus.

- 21 -

Figs. 36 to 39 are anatomic views depicting representative catheter-based devices and steps for implanting an implant system of the type shown in Fig. 35.

5        Fig. 40 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of an alternative embodiment of an implant system that forms a circumferential loop that applies force vectors to tissue  
10    in the region of the posterior mitral valve annulus.

      Fig. 41 is a perspective view of an elastic right heart implant that can, when implanted in the right atrium, affect the shape and/or function of a mitral valve annulus in the left atrium.

15        Fig. 42 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of the right heart implant shown in Fig. 41.

20        Fig. 43 is an anatomic superior perspective view of the left and right atriums, with portions broken away and in section to show the presence of the right heart implant shown in Fig. 41.

      Figs. 44A and 44B are, respectively, a top and side view of a plastically deformable right heart implant that  
25    can, when implanted in the right atrium, affect the shape and/or function of a mitral valve annulus in the left atrium.

30        Fig. 45 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of the right heart implant shown in Figs. 44A and 44B, prior to being plastically deformed.

35        Fig. 46 is an anatomic superior perspective view of the left and right atriums, with portions broken away and in section to show the presence of the right heart

- 22 -

implant shown in Figs. 44A and 44B, prior to being plastically deformed.

Fig. 47 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and  
5 in section to show a catheter-based tool that plastically deforms the implant shown in Figs. 44A and 44B.

Fig. 48 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of the right heart  
10 implant shown in Figs. 44A and 44B, after being plastically deformed.

Fig. 49 is an anatomic superior perspective view of the left and right atriums, with portions broken away and in section to show the presence of the right heart  
15 implant shown in Figs. 44A and 44B, after being plastically deformed.

Fig. 50 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of an implant deployed in  
20 the great cardiac vein and anchored to the septum in the right atrium.

Fig. 51 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and in section to show the presence of the implant shown in  
25 Fig. 50, with an appendage that compresses tissue in, at or near the septum in opposition to a portion of the anterior mitral valve annulus in the left atrium.

Fig. 52 is an anatomic anterior perspective view of the left and right atriums, with portions broken away and  
30 in section to show the presence of an implant system that includes two inter-atrial bridging elements with posterior regions anchored in the great cardiac vein and an anterior region anchored high on the interatrial septum, and further including an appendage that  
35 compresses tissue in, at or near the septum in opposition

- 23 -

to a portion of the anterior mitral valve annulus in the left atrium.

**Detailed Description**

Although the disclosure hereof is detailed and exact  
5 to enable those skilled in the art to practice the invention, the physical embodiments herein disclosed merely exemplify the invention, which may be embodied in other specific structure. While the preferred embodiment has been described, the details may be changed without  
10 departing from the invention, which is defined by the claims.

**I. Trans-Septal Implants for Direct Shortening of the Minor Axis of a Heart Valve Annulus**

**A. Implant Structure**

15 Figs. 10A and 10B show embodiments of an implant 10 that is sized and configured to extend across the left atrium in generally an anterior-to-posterior direction, spanning the mitral valve annulus. The implant 10 comprises a spanning region or bridging element 12 having  
20 a posterior tissue anchoring region 14 and an anterior tissue anchoring region 16.

The posterior anchoring region 14 is sized and configured to be anchored in a region of atrial tissue above the posterior mitral valve annulus. This region is  
25 preferred, because it generally presents more tissue mass for obtaining purchase of the posterior anchoring region 14 than in a tissue region at or adjacent to the posterior annulus. Engagement of tissue at this supra-annular location also avoids encroachment of and risk of  
30 injury to the circumflex coronary artery.

The anterior anchoring region 16 is sized and configured to be anchored, upon passing into the right atrium through the septum, to tissue in or near the right atrium. For example, as is shown in Figs. 10A and 10B,

- 24 -

the anterior anchoring region 16 may be anchored to a region of fibrous tissue in the interatrial septum. As shown, the anchoring site is desirably superior to the anterior annulus at about the same elevation or higher than the elevation of the posterior tissue anchoring region 14. In the illustrated embodiment, the anterior anchoring region 16 is anchored at or near the inferior rim of the fossa ovalis. As will be described later, the anterior anchoring region 16 can be anchored at a more superior position in the septum, e.g., at or near the superior rim of the fossa ovalis. The anterior anchoring region 16 can also be anchored in a more superior or inferior position in the septum, away from the fossa ovalis, provided that the anchoring site does not harm the tissue region.

As will be described in greater detail later, in an alternative embodiment (see, e.g., Figs. 33B and 33C), the anterior anchoring region 16, upon passing through the septum into the right atrium, may be anchored within or otherwise tethered to the superior vena cava (SVC) or the inferior vena cava (IVC), instead of to the septum itself.

In use, the spanning region or bridging element 12 can be placed into tension between the two tissue anchoring regions 14 and 16. The implant 10 thereby serves to apply a direct mechanical force generally in posterior to anterior direction across the left atrium. The direct mechanical force can serve to shorten the minor axis of the annulus. In doing so, the implant 10 can also reactively reshape the annulus along its major axis and/or reactively reshape other surrounding anatomic structures. It should be appreciated, however, the presence of the implant 10 can serve to stabilize tissue adjacent the heart valve annulus, without affecting the length of the minor or major axes.

- 25 -

It should be appreciated that, when situated in other valve structures, the axes affected may not be the "major" and "minor" axes, due to the surrounding anatomy. It should also be appreciated that, in order to be  
5 therapeutic, the implant 10 may only need to reshape the annulus during a portion of the heart cycle, such as during late diastole and early systole when the heart is most full of blood at the onset of ventricular systolic contraction, when most of the mitral valve leakage  
10 occurs. For example, the implant 10 may be sized to produce small or negligible displacement of the annulus to restore or enhance inward movement of the annulus during late ventricular diastolic relaxation, as the annulus dilates and becomes restricted by the implant 10.

15 The mechanical force applied by the implant 10 across the left atrium can restore to the heart valve annulus and leaflets a more normal anatomic shape and tension. The more normal anatomic shape and tension are conducive to coaptation of the leaflets during late  
20 ventricular diastole and early ventricular systole, which, in turn, reduces mitral regurgitation.

In its most basic form, the implant 10 is made from a biocompatible metallic or polymer material, or a metallic or polymer material that is suitably coated,  
25 impregnated, or otherwise treated with a material to impart biocompatibility, or a combination of such materials. The material is also desirably radio-opaque or incorporates radio-opaque features to facilitate fluoroscopic visualization.

30 The implant 10 can be formed by bending, shaping, joining, machining, molding, or extrusion of a metallic or polymer wire form structure, which can have flexible or rigid, or inelastic or elastic mechanical properties, or combinations thereof. Alternatively, the implant 10  
35 can be formed from metallic or polymer thread-like or

- 26 -

suture material. Materials from which the implant 10 can be formed include stainless steel, nitinol, titanium, silicone, plated metals, elgiloy, and NP55.

The implant 10 can take various shapes and have various cross-sectional geometries. The implant 10 can have, e.g., a generally curvilinear (i.e., round or oval) cross-section, or a generally rectilinear cross section (i.e., square or rectangular), or combinations thereof.

#### 1. The Posterior Anchoring Region

10 The posterior tissue anchoring region 14 is sized and configured to engage tissue within the left atrium at a supra-annular position, i.e., engaging tissue in the left atrium wall above the posterior annulus.

In the illustrated embodiment, the posterior anchoring region 14 is shown to engage tissue generally at the level of the great cardiac vein, which travels adjacent to and in parallel to the majority of the posterior mitral valve annulus. This tributary of the coronary sinus can provide a strong and reliable fluoroscopic landmark when a radiopaque device is placed within it or contrast dye is injected into it. As previously described, engagement of tissue at this supra-annular location also lessens the risk of encroachment of and risk of injury to the circumflex coronary artery compared to procedures applied to the mitral annulus directly.

The great cardiac vein also provides a site where relatively thin, non-fibrous atrial tissue can be readily augmented and consolidated. To enhance hold or purchase of the posterior tissue anchoring region 14 in what is essentially non-fibrous heart tissue, the posterior tissue anchoring region 14 can be coupled to a posterior anchor 18 placed within the great cardiac vein. This makes possible the mechanical fixation of the posterior anchoring region 14 in a non-fibrous portion of the heart

- 27 -

in a manner that can nevertheless sustain appreciable hold or purchase on that tissue for a substantial period of time, without dehiscence, expressed in a clinically relevant timeframe.

5           In one embodiment (see Fig. 10A), the posterior anchor 18 comprises an integral part of the implant 10, being integrally joined to the posterior anchoring region 14 in a generally perpendicular relationship, forming a T-shape. In this arrangement, the posterior anchor 18  
10 comprises the cross-arm of the T-shape. The posterior anchor 18 is elongated sufficiently to traverse inside at least a portion of the great cardiac vein in medial and lateral directions from the posterior anchoring region 14.

15           In this arrangement, the posterior anchor 18 can be inserted in a laid-back, collapsed condition upon the posterior anchoring region 14, through the lumen of a tissue piercing needle from the left atrium through a wall of the great cardiac vein. The posterior anchor 18  
20 can be configured with an elastic memory such that, once free of the needle lumen, it springs open from the collapsed condition into the T-shape, to reside within the great cardiac vein. In this arrangement, the posterior anchor 18 can have a diameter of about 0.5 mm.

25           In the embodiment shown in Fig. 10B, the posterior anchor 18 comprises a separate structure to which the posterior anchoring region 14 is coupled during implantation. The coronary sinus provides an accessible intravascular site from the right atrium, through which  
30 the posterior anchor 18 of this type can be placed.

          In the embodiment shown in Fig. 10B, the posterior anchor 18 comprises mechanical stent-like structure. The stent-like structure is desirably relatively large (e.g., at least 10 mm to 20 mm in diameter) to present a large  
35 physical and radiopaque target for the posterior



- 28 -

anchoring region 14, or any other intra-atrial device attempting to enter or attach to an anchoring structure present within the great cardiac vein. The desired large physical size of the posterior anchor 18 further  
5 diminishes the likelihood of trauma to the circumflex coronary artery, in comparison to a situation where a smaller structure were placed in the great cardiac vein. A smaller physical target could be more readily missed, and trauma to surrounding tissues could result. Of  
10 course, a smaller structure (e.g., approaching 5 mm in diameter) or a larger structure (e.g., approaching 30 mm in diameter) could be selected for use, depending upon the particular therapeutic objectives that are intended.

It should be appreciated that non-fibrous tissue at,  
15 above, or below the level of the great cardiac vein, e.g., in a range of about 5 to about 25 mm above the plane of the posterior mitral valve annulus, can be strengthened and consolidated in other ways. For example, tissue bulking agents or fibrosis caused, e.g.,  
20 chemically or by heat can be used to strengthen and consolidate regions of atrial tissue above the annulus for purchase or hold by the posterior tissue anchoring region 14.

## 2. The Anterior Anchoring Region

25 The anterior anchoring region 16 is sized and configured to engage firmly the fibrous tissue and the surrounding tissues in the right atrium side of the atrial septum. This fibrous tissue region provides a tissue fixation site of better integrity than muscle in  
30 terms of devices pulling through. The septum is the most fibrous tissue structure in its own extent in the heart. Surgically handled, it is usually one of the only heart tissues into which sutures actually can be placed and can be expected to hold without pledgetts or deep grasps into  
35 muscle tissue, where the latter are required.

- 29 -

As Fig. 10 shows, the anterior tissue anchoring region 16 passes through the septal wall at a supra-annular location above the plane of the anterior mitral valve annulus. The supra-annular distance on the anterior side can be generally at or above the supra-annular distance on the posterior side. As before pointed out, the anterior tissue anchoring region 16 is shown in Fig. 10 at or near the inferior rim of the fossa ovalis, although other more inferior or more superior sites can be used within or outside the fossa ovalis, taking into account the need to prevent harm to the septal tissue and surrounding structures.

By engaging tissue at this supra-annular level within the right atrium, which is fully outside the left atrium and spaced well above the anterior annulus, the implant 10 avoids the impracticalities of endovascular attachment at or adjacent to the anterior annulus, where there is just a very thin rim of annulus tissue that is bounded anteriorly by the anterior leaflet, inferiorly by the aortic outflow tract, and medially by the atrioventricular node of the conduction system. The anterior annulus is where the non-coronary leaflet of the aortic valve attaches to the mitral annulus through the central fibrous body. Anterior fixation of the implant 10 in the supra-annular level within the right atrium (either to the septum or in a vena cava) avoids encroachment of and risk of injury to both the aortic valve and the AV node.

The purchase of the anterior tissue anchoring region 16 in fibrous septal tissue is desirably enhanced by one or more anterior anchors 20. The anterior anchor or anchors 20 mechanically amplify the hold or purchase of the anterior anchoring region 16 in the fibrous tissue site. The anterior anchor or anchors 20 also desirably increase reliance, at least partly, on neighboring

- 30 -

anatomic structures of the septum to anchor and fix the position of the implant 10. Anticipating that pinpoint pulling forces will be applied by the anchoring region 16 to the septum, the forces acting on the anchor 20 should  
5 be spread over a moderate area, without causing impingement on valve, vessels or conduction tissues. The anchor 20 should also have a low profile configuration and highly washable surfaces to diminish thrombus formation for devices deployed inside the heart. As will  
10 be described in greater detail later, a septal brace may be used in combination with the anterior anchor or anchors 20 to distribute forces uniformly along the septum (see Fig. 33A). Alternatively, stents in the IVC or the SVC can be used as anchoring sites (see Fig. 33B  
15 and 33C), instead of anchoring directly to the septum.

Fixation of the posterior and anterior tissue anchoring regions 14 and 16 having radiopaque anchors and well demarcated fluoroscopic landmarks respectively at the supra-annular tissue sites just described, not only  
20 provides freedom from key vital structure damage -- e.g., to the circumflex artery, AV node, and the left coronary and non-coronary cusps of the aortic valve - but the supra-annular fixation sites are also not reliant on purchase between tissue and direct tension-loaded  
25 penetrating/biting/holding tissue attachment mechanisms. Instead, physical structures and force distribution mechanisms like stents can be used, which better accommodate the attachment of mechanical levers and through which potential tissue tearing forces can be  
30 better distributed. Further, the fixation sites do not require the operator to use complex imaging. Adjustment of implant position after or during implantation is also facilitated, free of these constraints. The fixation sites also make possible full intra-atrial retrieval of  
35 the implant 10 by endovascularly snaring and then cutting

- 31 -

the bridging element at either side of the left atrial wall, from which it emerges.

### 3. Orientation of the Spanning Region

In the embodiment shown in Fig. 10, the implant 10 is shown to span the left atrium beginning at a posterior point of anchorage superior to the approximate mid-point of the mitral valve annulus, and proceeding in an anterior direction in a generally straight path directly to the region of anterior anchorage in the septum. As shown in Fig. 10, the spanning region or bridging element 12 of the implant 10 is preformed or otherwise configured to extend in this essentially straight path above the plane of the valve, without significant deviation in elevation toward or away from the plane of the annulus, other than as dictated by any difference in elevation between the posterior and anterior regions of anchorage.

Lateral or medial deviations and/or superior or inferior deviations in this path can be imparted, if desired, to affect the nature and direction of the force vector or vectors that the implant 10 applies. It should be appreciated that the spanning region or bridging element 12 can be preformed or otherwise configured with various medial/lateral and/or inferior/superior deviations to achieve targeted annulus and/or atrial structure remodeling, which takes into account the particular therapeutic needs and morphology of the patient.

For example, as shown in Fig. 11, the implant 10 is shown to span the left atrium beginning at a posterior region of anchorage that is closer to a lateral trigone of the annulus (i.e., farther from the septum). Alternatively, the posterior region of anchorage can be at a position that is closer to a medial trigone of the annulus (i.e., closer to the septum). From either one of these posterior regions of anchorage, the implant 10 can

- 32 -

extend in an anterior direction in a straight path directly to the region of anterior anchorage in the septum. As shown in Fig. 11, like Fig. 10, the spanning region or bridging element 12 of the implant 10 is  
5 preformed or otherwise configured to extend in an essentially straight path above the plane of the valve, without significant deviation in elevation toward or away from the plane of the annulus, other than as dictated by the difference in elevation, if any, between the  
10 posterior and anterior regions of anchorage.

Regardless of the particular location of the posterior region of anchorage (see Fig. 12), the spanning region or bridging element 12 of the implant 10 can be preformed or otherwise configured to arch upward above  
15 the plane of the valve toward the dome of the left atrium. Alternatively (see Fig. 13), the spanning region or bridging element 12 of the implant 10 can be preformed or otherwise configured to dip downward toward the plane of the valve toward the annulus, extending close to the  
20 plane of the valve, but otherwise avoiding interference with the valve leaflets. Or, still alternatively (see Fig. 14), the spanning region or bridging element 12 of the implant 10 can be preformed or otherwise configured to follow a curvilinear path, bending around a trigone  
25 (medial or lateral) of the annulus before passage to the anterior anchorage region.

Various combinations of lateral/medial deviations and superior/inferior deviations of the spanning region or bridging element 12 of the implant 10 are of course  
30 possible. For example, as shown in Fig. 15, the spanning region or bridging element 12 can follow a curvilinear path bending around a trigone (medial or lateral) of the annulus as well as elevate in an arch away from the plane of the valve. Or, as shown in Fig. 16, the spanning  
35 region or bridging element 12 can follow a curvilinear

- 33 -

path bending around a trigone (medial or lateral) of the annulus as well as dip toward the plane of the valve.

Regardless of the orientation, more than one implant 10 can be installed to form an implant system 22. For example, Fig. 17 shows a system 22 comprising a lateral implant 10L and a medial implant 10M of the types previously described. Fig. 17 shows the implants 10L and 10M being fixed at a common anterior anchorage region. It should be appreciated that the implants 10L and 10M can include spaced apart anterior anchorage regions.

One or both of the implants 10L and 10M can be straight (as in Fig. 11), or arch upward (as in Fig. 12), or bend downward (as in Fig. 13). A given system 10 can comprise lateral and medial implants 10L and 10M of different configurations. Also, a given system 22 can comprise more than two implants 10.

Fig. 18 shows a system 22 comprising two curvilinear implants 10L and 10M of the type shown in Fig. 14. In Fig. 18, the curvilinear implants 10L and 10M are shown to be anchored at a common posterior anchorage region, but the implants 10 can proceed from spaced apart posterior anchorage regions, as well. One or both of the curvilinear implants 10L and 10M can be parallel with respect to the plane of the valve (as in Fig. 14), or arch upward (as in Fig. 15), or bend downward (as in Fig. 16). A given system 22 can comprise curvilinear implants 10L and 10M of different configurations.

Fig. 19 shows a system 22 comprising a direct middle implant 10D, a medial curvilinear implant 10M, and a direct lateral implant 10L. One, two, or all of the implants 10 can be parallel to the valve, or arch upward, or bend downward, as previously described.

#### **B. Anchoring elements**

##### **1. Within the Great Cardiac Vein**

As before explained, the posterior tissue anchoring

- 34 -

region 14 desirably includes one or more posterior anchors 18 placed in the great cardiac vein to enhance its purchase in supra-annular tissue in the left atrium.

The posterior anchor 18 can be variously  
5 constructed. The anchor 18 may be rigid, or flexible, or elastic, or malleable, or solid, or porous. The anchor 18 can sized and configured to provide a localized anchoring site, or be elongated and extend medially and laterally from the intended anchoring site to better consolidate  
10 atrial tissue at the level of the vein along the length of the vein.

As shown in Fig. 20, the anchor 18 can comprise a stent-like structure 24 that is sized and configured to be introduced into the great cardiac vein, e.g., through  
15 the coronary sinus os in the right atrium (as will be described in greater detail later). The structure 24 can comprise an expandable scaffold, which can take the form of a self-expanding stent, or a malleable structure that is expanded by means of an interior force, e.g., a  
20 balloon. The structure 24 can be flexible, or semi-rigid, or rigid, or have regions of different mechanical characteristics.

Alternatively, the anchor 18 can comprise a preformed, non-expandable hollow tube or solid rod of a  
25 pre-determined shape, which is sized and configured to be advanced into the great cardiac vein. Still alternatively, the anchor 18 can comprise an inert biocompatible bulking material injected into the vein, which cures to possess a desired mechanical property. Or,  
30 the anchor 18 can include a hollow structure that is at least a partially-filled with an inert biocompatible material, which cures to possess a desired mechanical property.

Regardless of the particular configuration, the  
35 anchor 18 is desirably radio-opaque or incorporates

- 35 -

radio-opaque features to facilitate fluoroscopic visualization when positioned in a tributary of the coronary sinus.

As Fig. 21 shows, the anchor 18 may be held in position within the vein by gripping the surrounding vessel wall, e.g., by barbs, tines, or the like. If desired, the anchor 18 may be further secured by suture, adhesive; or like material within the vein. The anchor 18 can incorporate roughened or porous surfaces and/or be coated with or allow injection of other materials (e.g., polyester fabric, irritative agents, or drug agents) to promote tissue in-growth. To enhance fibrosis and potentially diminish the likelihood of tissue dehiscence in and around the great cardiac vein at the time the anchoring region 14 is used, the anchor 18 may be placed within the great cardiac vein a number of weeks in advance of the anchoring region 14. The number of weeks may vary, but a majority of patients may be expected to have some healing by four weeks as a minimum. In this arrangement (see Figs. 22 and 23), the posterior anchoring region 14 is sized and configured to be manipulated within the left atrium outside the vein, and to lock into or otherwise gain purchase with the anchor 18 that resides within the vein. For example, the posterior anchoring region 14 can comprise a hook or T-shaped structure that locks from outside the vein into the material or structure of the anchor 18 residing within the vein. Alternatively, as shown in Fig. 10A, if the integrated cross-arm of the T is elongated to the extent that it traverses inside the coronary venous system along a sufficient length of the great cardiac vein, the cross-arm can itself serve as the anchor 18 with a separately deployed structure. Alternatively, the posterior anchoring region 14 (or the entire implant 10, for that matter) can comprise suture material that is



- 36 -

threaded from outside the vein through the material or structure of the anchor 18 residing within the vein.

## 2. Anchoring To Fibrous Septal Tissue

5 The anterior anchoring region 16 is sized and configured to pass through the septum and project into the right atrium. There, the anterior anchor 20 captures the anterior anchoring region 16 and holds the anchoring region 16 against the fibrous and surrounding muscular tissue of the septum in the right atrium.

10 The anterior anchor 20 can be variously constructed. In the illustrated embodiment (see, e.g., Figs. 10, 22, and 23), the anterior anchor 20 takes the form, fit, and function of an anchor button that is secured to the anterior anchoring region. The anchor button 20 includes  
15 barbed stays 25 that brace against the septum. The stays 25 can be crimped to the anterior anchoring region 16 to maintain a desired degree of tension on the spanning region or bridging element 12 within the left atrium. An anchor button 22 can be located only on the right atrium  
20 side of the septum, or both left and right atrium sides of the septum.

Alternatively, the anterior anchoring region 16 (or the entire implant 10, for that matter) can comprise suture material that is threaded through the fibrous wall  
25 of the septum, with or without the use of an anchor button or the like. In the latter case a more proximal vena caval anchor would supplant the need for using the inter-atrial septum as an anchor.

As will be described later, the anchoring site can  
30 be within either the SVC or IVC, instead of to the septum.

## C. Implantation

The implants 10 or implant systems 22 as just described lend themselves to implantation in a heart  
35 valve annulus in various ways. The implants 10 or implant

- 37 -

systems 22 can be implanted, e.g., in an open heart surgical procedure. Alternatively, the implants 10 or implant systems 22 can be implanted using catheter-based technology via a peripheral venous access site, such as  
5 in the femoral or jugular vein or femoral artery (via the IVC or SVC) under image guidance, or trans-arterial retrograde approaches to the left atrium through the aorta also under image guidance.

Alternatively, the implants 10 or implant systems 22  
10 can be implanted using thoracoscopic means through the chest, or by means of other surgical access through the right atrium, also under image guidance.

Image guidance includes but is not limited to fluoroscopy, ultrasound, magnetic resonance, computed  
15 tomography, or combinations thereof.

Figs. 24 to 30 show a representative embodiment of the deployment of an implant 10 of the type shown in Fig. 10 by a percutaneous, catheter-based procedure, under image guidance.

20 Percutaneous vascular access is achieved by conventional methods into the femoral or jugular vein. As Fig. 24 shows, under image guidance, a first catheter 26 is steered through the vasculature into the right atrium. It is the function of the first catheter 26 to deploy the  
25 posterior anchor 18 into the great cardiac vein through the coronary sinus. Catheter access to the coronary sinus can be achieved through either a femoral vein to IVC or SVC route (in the latter case, for a caval brace) or an upper extremity or neck vein to SVC or IVC route (in the  
30 latter case, for a caval brace). In the case of the SVC, the shortest access is from the upper extremity or neck venous system; however, the IVC can also be access by passing through the SVC and right atrium. Similarly the shortest access to the IVC is through the femoral vein;  
35 however the SVC can also be access by passing through the

- 38 -

IVC and right atrium. Figs. 24 to 30 show access through a SVC route for purposes of illustration. In a later described implantation technique (see Figs. 36 to 39), access through an IVC route is shown for purposes of illustration.

5 The first catheter 26 advances the anchor 18, e.g., through the coronary sinus os in the right atrium, into the great cardiac vein above and in parallel to the posterior mitral valve annulus. A guide wire (not shown) may be used to guide the advancement. The anchor 18 is extended to a length sufficient to accommodate the desired site of fixation for the posterior anchoring region 14 of the implant 10. The length of the posterior anchor may extend from 20 mm to 200 mm as it lies inside the coronary venous system. The desired position of the posterior anchor 18 can be secured, e.g. by self-expansion or the use of a balloon to cause expansion within the vein, or it may require no conformational change from its shape inside the delivery catheter.

20 As Fig. 25 shows, upon securing the position of the posterior anchor 18 within the vein, the first catheter 26 is withdrawn (the guide wire, if used, may be left inside the posterior anchor 18 within the coronary vein), and a second catheter 28 is steered through the vasculature into the right atrium. The second catheter 28 carries the anterior anchor 20, which it fixes to the septum. The second catheter 28 also carries a distal needle (not shown), which is deployed to pierce the septum between the right and left atrium. In Fig. 25, the needle pierces the fossa ovalis near its inferior rim. The fossa ovalis is selected because it constitutes a safe structure to traverse and has an anatomic landmark that can be readily accessed by conventional intravascular techniques and pierced for the purpose of gaining access to the left atrium from the right atrium

- 39 -

through the septum. Catheter access to the fossa ovalis can be achieved through either a femoral-IVC or internal jugular-SVC route (a femoral-SVC route is shown simply for purposes of illustration). As Fig. 25 shows, once  
5 access between the right and left atriums is opened, a guide wire 32 is advanced trans-septally through the needle catheter 28 into the left atrium.

The second catheter 28 is withdrawn (Fig. 26A shows its absence). Under image guidance, an implant delivery  
10 catheter 34 is advanced over the guide wire 32 trans-septally through the fossa ovalis puncture (through the already delivered anchor 20, which is attached there) and into the left atrium. Alternatively, the implant delivery catheter 34 can be deployed trans-septally by means of  
15 surgical access through the right atrium.

Under image guidance, the implant delivery catheter 34 is directed to a targeted posterior anchoring site at the level where the posterior anchor 18 resides within the great cardiac vein. The implant delivery catheter 34  
20 can include an on-board distal steering mechanism, to direct the catheter 34 to the intended site with image guidance. Alternatively, or in combination (see Fig. 26B), the anchor 18 residing within the great cardiac vein can carry one or more magnetic elements 210 along  
25 its length (either as part of the anchor 18 or within a separately delivered catheter that temporarily supplies the magnetic force required), which coincide with the targeted anchoring site(s). In this arrangement, the distal end of the implant delivery catheter 34 can  
30 include a magnetic element 212 or soft ferromagnetic material that is magnetically attracted to the magnetic element within the great cardiac vein at the intended anchoring site.

Once the implant delivery catheter 34 has located  
35 the targeted anchoring site (see Fig. 27A), the implant

- 40 -

delivery catheter 34 is manipulated by imagining, magnetic guidance catheter or other means described in the present invention or in standard interventional or surgical practice, to puncture atrial tissue at the anchoring site into the great coronary vein. The posterior anchoring region 14 of the implant 10 is advanced from the implant delivery catheter 34 into the great cardiac vein (as Fig. 27B shows) to attach to the posterior anchor 18 that resides there, as illustrated in this case with a hooking attachment locking mechanism (as Fig. 27C shows). Alternatively, the anchoring region 14 can include a grasper that grasps through tissue and into a strut of the posterior anchor 18 inside the great cardiac vein to gain attachment.

As Fig. 28 shows, once attachment between the posterior anchoring region 14 and the posterior anchor 18 is made, the implant delivery catheter 34 is drawn out of the great cardiac vein and anteriorly across the left atrium. The spanning region or bridging element 12 of the implant 10 is thereby deployed from the catheter 34 within the left atrium. In this way, the anterior anchoring region 16 is lead back through the septum and into the right atrium.

As Fig. 29 shows, the implant delivery catheter 34 can exert a pulling force on the spanning element or bridging element 12 as it slides through the already attached anterior anchoring region 16 from within the right atrium, to place the spanning region or bridging element 12 in a desired amount of tension. Alternatively, anterior anchoring region 16 can be released from the implant delivery catheter 34 and a suitable grasping instrument (for example, a 7 French grasper) can be deployed in the right atrium to take hold of the anchoring region 16 in the right atrium to place the spanning region 12 in a desired amount of tension, while

- 41 -

the anterior anchoring region 16 is slid forward by the guiding catheter to achieve the proper tensioning. Various other surgical techniques and manipulations can be employed to place the spanning element 12 into  
5 tension. For example, the anterior anchor 16 can include a cinch release mechanism, which can be snipped with a cutting tool and another anchor threaded over the proximal wire component of the bridging or spanning  
10 element 12. The latter is snipped when adjustments have been finalized.

Regardless of the surgical manipulation and/or instrumentation used, pulling inwardly toward the left atrium on the anterior anchoring region 16 (either from within the right atrium by means of the implant delivery  
15 catheter 34 or a separate gripping tool) exerts a pulling force on posterior atrial tissue in the region where the posterior anchoring region 14 is attached to the posterior anchor 18. The pulling force draws the posterior atrial tissue inwardly toward the anterior  
20 atrial tissue of the left atrium. The existence of the elongated posterior anchor 18 serves to consolidate the length of the great cardiac vein, thereby distributing the pulling force laterally and medially. The pulling force can serve to shorten the annulus along its minor  
25 axis. The presence of the anchor 18 within the great cardiac vein consolidates the length of the great cardiac vein into a unitary physical structure, which, when pulled upon at least at one point, serves to compress the whole posterior annulus.

30 The physician can elect to monitor the incidence of mitral regurgitation by various conventional means, e.g., by contrast ventriculography or by echocardiographic Doppler assessment, as tension is progressively applied to the implant 12. If the physician chooses this  
35 approach, the physician can dynamically adjust tension on

- 42 -

the implant 12 to achieve a desired diminution or elimination of the incidence or mitral regurgitation.

As Fig. 29 shows, once the implant 12 is satisfactorily positioned and/or the desired therapeutic result is achieved, the physician introduces a tool 36 that crimps a clip 38 or a functionally equivalent mechanism to the anterior anchoring region 16, to hold fast the anterior anchoring region 16 to the anchor button 20. Alternatively, the anterior anchoring region 16 can be threaded, and a nut delivered and threaded to the region 16 to retain the anterior anchoring element 16 in the desired degree of tension. As Fig. 30 shows, the anterior anchoring region 16 is cut next to clip 38 (or nut), ending the installation, and the intravascular tool or tools are withdrawn.

The projection of the anterior anchoring region 16 into the right atrium facilitates repositioning, retensioning, and/or retrieval of the implant 12 from the right atrium, if necessary or desired.

## 20 II. Implant Systems for Achieving Mitral Annulus Unloading

### A. System Overview

The trans-septal embodiments just described with straight or linear bridging elements apply a main force vector that is directed essentially across the left atrium (i.e., at about a fifteen to less than forty-five degree vector above the horizontal) from a posterior region above the mitral valve annulus to an anterior septal tissue region, which is also above the mitral valve annulus. Use of the implant 10 or implant system 22 for this purpose can provide significant amelioration of mitral regurgitation.

Fig. 31 shows an implant system 40 for treating mitral regurgitation that applies, either alone or in conjunction with horizontal force vectors, a superior or

- 43 -

upward lifting force vector(i.e., at a vector greater than about forty-five degrees above the horizontal) upon tissue in the region of the mitral valve annulus. The upward lifting force releases or dissipates tension on the mitral valve annulus from the posterior mitral annulus of the left heart into the implant and brace system of the right heart. It also imposes a more direct vertical force vector component upon atrial tissue between the great cardiac vein and the left ventricle so that the application of horizontal force vectors more directly leads to a desired compressive effect upon the annulus. By applying a vertical force to atrial tissue between the great cardiac vein and the ventricle, less horizontal inward movement of the great cardiac vein is required before a directly compressive effect is applied to the annulus.

Tension on the mitral valve annulus can arise when the left ventricle and annulus become dilated. The magnitude of the tension on the annulus can be significant in situations involving functional mitral regurgitation, particularly functional mitral regurgitation of at least Grade 2+. When the annulus is under tension, the mitral chordae become tense, pulling the coaptation points down and away from each other. Also the annulus-to-leaflet junction becomes taut. An analogy is midline poles (the annulus) holding up a bi-leaf tent (the leaflets), with ropes and stakes (the chordae) holding the tent leaves tautly (the taut leaflets) to the ground (the papillary muscles). If there is insufficient leaflet tissue to coapt in systole, functional mitral regurgitation is the result. This is believed to be the result of the tension that dilation places on the annulus, working in synchrony with the pulling away of the walls of the ventricle.

The implant system 40 imposes a lifting force vector



- 44 -

on the annulus (a ventricular structure) by pulling upward on an atrial structure. To achieve this outcome, the system 40 includes a tissue consolidating component 42A, which consolidates the great cardiac vein into a unified physical structure along its length. The system 490 also includes bonding means 42B for conjoining or bonding the great cardiac vein to the ventricle in the region between the great cardiac vein and the ventricle. In this way, as the system 40 pulls upward on a consolidated great cardiac vein (an atrial structure), a lifting force vector is transferred by the conjoined great vein-ventricle tissue region upon the ventricle.

More particularly, the implant system 40 shown in Fig. 31 comprises a tissue-consolidating component 42A. The tissue-consolidating component 42A consolidates the great cardiac vein into a unified physical structure along its length, so that a lifting force applied at one or more points along the length of the great cardiac vein serves to lift the entire great cardiac vein along its length. In the embodiment shown in Fig. 31, the tissue-consolidating component 42A resides, in most part, in the great cardiac vein. It can be sized and configured the same way as the posterior anchor 18 previously described. The tissue-consolidating component 42 can also be introduced and stabilized in the great cardiac vein in the same fashion as already described.

As shown in Fig. 31, the tissue-consolidating component 42A is desirably ring-like, extending from the great cardiac vein to the coronary sinus or adjacent the majority of the length of the posterior mitral annulus within the great cardiac vein. As such, the tissue-consolidating component 42A is located some 5mm to 20mm above the ventricular muscle. The tissue consolidating component 42A desirably incorporates radio-opaque features to facilitate fluoroscopic visualization.

- 45 -

The bonding means 42B conjoins or bonds the great cardiac vein to the ventricle in the region between the great cardiac vein and the ventricle. The means 42B bonds non-fibrous, thin atrial tissue at and below the great  
5 cardiac vein to the mitral valve annulus. The means 42B in effect bonds the component 42A that consolidates the great cardiac vein to the left ventricular muscle base proximate to the posterior mitral annulus, so that lifting and horizontal forces applied to the component 42  
10 are directly transferred to lifting and/or compression of the annulus itself. The means 42B also diminishes the possibility of a Type 1 left ventricular rupture between the great cardiac vein and the top of the left ventricle as a result of the forces applied to the component 42  
15 over time.

The means 42B for bonding of the great cardiac vein to the ventricle can take various forms. Mechanical means, such as staples can be attached between the component 42A and tissue in the left ventricle. Drugs,  
20 and/or irritative agents, and/or heat (e.g., radiofrequency heating), and/or chemical agents can be applied to tissue in the region. Alternatively, or in combination, tissue at or near the great cardiac vein can be subject to fibrosis to reinforce the tissue and  
25 elevate the pull-through threshold of the component 42A. Fibrosis can be accomplished by the use of polyester coatings, drugs, irritative agent elutions, or combinations thereof. Fibrosis can also be achieved by the application of heat.

30 As shown in Fig. 33D, alternatively, or in combination with the above, the means 42B can comprise an array of magnets 220 carried by the tissue-consolidating component 42A and an array of magnets or soft ferromagnetic elements 222 that are surgically placed  
35 beneath the posterior annulus. The polarity of the

- 46 -

magnets 220 is selected to magnetically attract the magnetic or soft ferromagnetic elements 222. Of course, if the elements 222 were magnets, soft ferromagnetic materials could be used within the great cardiac vein in lieu of the magnets 220.

In the illustrated embodiment, the elements 222 are carried for implantation by expandable or inflatable bodies 224, e.g., balloons. The bodies 224 can be individually placed by deployment of a catheter through the aortic valve into the left ventricle, into spaced apart locations under the posterior leaflet. Once implanted, the bodies 244 can be expanded or inflated to stabilize the position of the elements 222, e.g., by injection of saline. The magnetically attraction between the magnets 220 and elements 222 draws the two tissue region together, thereby bonding the great cardiac vein to the posterior annulus.

As shown in Fig. 31, the system 40 also comprises one or more lifting components 44. The lifting component 44 has a posterior anchoring region 46 within the left atrium that couples to the tissue-consolidating component 42A residing within the great cardiac vein. Desirably, at least one lifting component 44 has a posterior anchoring region 46 coupled to the tissue-consolidating element 42A superior to and in alignment with the approximate mid-point of the mitral valve annulus, as Fig. 31 shows. As Fig. 32 shows, other lifting elements 44 can be deployed on medial and/or lateral sides of the posterior annulus, at or near one or both trigones.

As Figs. 31 and 32 show, at least one of the lifting components 44 has a spanning region or bridging element 48 that is preformed or otherwise configured to extend high within the left atrium, upward from its anchoring point with the tissue-consolidating component 42A, and toward the dome of the left atrium.

- 47 -

The lifting component 44 also includes an anterior anchoring region 50 that passes out of the left atrium and into the right atrium through fibrous tissue of the high septum. In Fig. 31 and 32, the anterior anchoring region 50 is shown anchored at or near the superior rim of the fossa ovalis. As will be described in greater detail later (and as is shown in Figs. 33B and 33C), the anterior region of the lifting component 44 can be anchored to or otherwise tethered within the SVC or IVC, and not anchored to the septum itself. In this arrangement (see Fig. 33B), the lifting component 44 with the high atrial bridging element 48 can pass through the septum high in the fossa ovalis, without anchoring to septal tissue, and be anchored or tethered instead to a stent in the SVC. This arrangement is believed to maximize the effect of the lifting vector. Alternatively (see Fig. 33C), the lifting component 44 (desirably without a high atrial bridging element 48) can pass through the septum low in the fossa ovalis, without anchoring to septal tissue, and be anchored or tethered instead to a stent in the IVC.

The lifting component 44 can be formed by bending, shaping, joining, machining, molding, or extrusion of a metallic or polymer wire form structure, which can have flexible or rigid, or inelastic or elastic mechanical properties. The lifting component 44 can take various shapes and have various cross-sectional geometries. The lifting component can have, e.g., a generally curvilinear (i.e., round or oval) cross-section, or a generally rectilinear cross section (i.e., square or rectangular), or combinations thereof.

Desirably, the lifting component 44 is "elastic." The lifting component 44 is sized and configured to possess a normal, unloaded, shape or condition, in which the component is not in compression or tension. The

- 48 -

material of the lifting component 44 is selected to possess a desired spring constant. The spring constant imparts to the component 44 the ability to be elastically stretched and placed in tension in response to external  
5 pulling applied at the anterior anchoring region 50 when the posterior anchoring region 46 is coupled to the tissue consolidating component 42A. When in tension, the lifting component 44 applies an upward force (e.g., with a force vector of great than about 45° above horizontal)  
10 upon the tissue-consolidating component 42A.

The system 40 further comprises an anchor 52 sized and configured to be coupled to the anterior anchoring region 50 of the lifting component 44 in the right heart. The anchor 52 holds the lifting component 44 in tension  
15 against the septum in the right atrium. In an alternative embodiment, stents or equivalent non-obstructing anchors in the IVC or SVC can serve as anchoring sites for the lifting component or components 44.

The lifting component and anchoring component  
20 desirably incorporates radio-opaque features to facilitate fluoroscopic visualization.

As Fig. 32 shows, the system 40 may include more than one lifting component 44. Multiple lifting components 44 may be coupled at spaced locations along  
25 the consolidating component 42A, for example, three lifting components 44 coupled at or near the mid posterior annulus and the lateral and medial trigones. The anterior anchoring regions 50 of the lifting components 44 may be passed through a single opening at  
30 or near the superior rim of the fossa ovalis in the high interatrial septum into the right atrium, and there joined and retained by a single anchor 32.

The arched lifting components 44, which elevate a consolidated great cardiac vein vertically, while  
35 bringing it horizontally inward toward the septum,

- 49 -

provide mural support to the wall of the left atrial chamber.

The components of the system 40, when assembled in the manner shown in Figs. 31 to 33, unload tension from the mitral annulus in late diastole and early systole dynamically through dissipation of some of the wall tension that tends to expand the annulus. The great cardiac vein, reinforced and consolidated by the consolidating component 42, becomes the lever upon which the spring-like lifting component 44 or components act to dynamically unload the base of the left ventricle by dissipating ventricular muscle wall tension and relaying it through the now-consolidated AV groove.

As the ventricle starts to fill with blood, the spring-like lifting component 44 or components become maximally loaded at end-diastole and in early systole, when the mitral valve area is the least and functional mitral regurgitation is most likely to occur. The spring energy unloads the ventricular muscular wall tension at end-diastole and early systole, and the annulus is relieved of tension (at least partially) enough to release or dissipate tension from tented mitral leaflets, thereby allowing improved re-approximation of the mitral leaflets especially in late diastole and early systole to allow closure.

The system 40 may also, as a primary or secondary effect, result in re-shaping the annulus.

As Fig. 34 shows, the system 40 can include auxiliary implant components 60 that extend either across the minor axis of the annulus to shorten the minor axis, or across the major axis of the annulus to shorten or lengthen the major axis, or both minor and major axes can be treated simultaneously. Such implant components 60 can be sized and shaped so that, in use, they apply, in conjunction with the unloading force of the system 40,

- 50 -

one or more direct mechanical forces along the minor axis, major axis, or both axes of the annulus, to reshape the annulus. The lifting forces imposed by the system 40 lessen the horizontal leading length of atrial tissue between the great cardiac vein and the ventricle, which must be moved in order to achieve any compressive effect on the posterior annulus imposed by forces applied to an anchor in the great cardiac vein. Thus, the posterior-to-anterior force vectors and/or the medial-to-lateral force vectors imposed by the auxiliary component or components 60 can work in tandem to achieve the desired result. The remodeling effects of the auxiliary component or components 60 can thereby be magnified in the presence of the annulus lifting forces imposed by the system 40.

The auxiliary implant components 60 can be made -- e.g., by bending, shaping, joining, machining, molding, or extrusion -- from a biocompatible metallic or polymer material, or a metallic or polymer material that is suitably coated, impregnated, or otherwise treated with a material to impart biocompatibility, or a combination of such materials. The material is also desirably radio-opaque or incorporates radio-opaque features to facilitate fluoroscopic visualization. The auxiliary implant components desirable include struts that engage supra-annular tissue.

Further details of implants that can be used as auxiliary implant components 60 are shown in co-pending United States Patent Application Serial No. 10/677,104, filed October 1, 2003, and entitled "Devices, Systems, and Methods for Reshaping a Heart Valve Annulus," which is incorporated herein by reference.

#### **B. Implantation**

The implant systems 40 as just described lend themselves to implantation in a left and right heart in various ways. The systems can be implanted, e.g., in an

- 51 -

open heart surgical procedure. Alternatively, the systems can be implanted using catheter-based technology via a peripheral venous access site, such as in the femoral, jugular, subclavian vein or femoral artery, under image  
5 guidance. Figs. 24 to 30 show a representative embodiment of a percutaneous, catheter-based procedure that, under image guidance, can implant the system 40.

Alternatively, the systems 40 can be implanted using thoroscopic means through the chest, or by means of  
10 other surgical access through the right atrium, also under image guidance. Image guidance includes but is not limited to fluoroscopy, ultrasound, magnetic resonance, computed tomography, or combinations thereof.

It is believed that the implant system 40 as  
15 described can be sized and configured to allow leaflets to coapt in the face of functional mitral regurgitation above Grade 1+, including up to Grade 4+, which could be ameliorated at least to some significant extent. The system provides rapid deployment, facile endovascular  
20 delivery, and full intra-atrial retrievability. The system also provides strong fluoroscopic landmarks.

### III. Right Heart Bracing

As Fig. 33A shows, any intra-atrial system with a trans-septal component deployed within the left atrium -  
25 e.g., the systems 40 shown in Figs. 31 to 32 or the implants 10 shown in Figs. 10 to 19 -- can also include right heart components 54 that act as braces to stabilize the septal anchor 20 or 52 relative to the tissue-consolidating component 18 or 42. As Figs. 33B and 33C  
30 show, any intra-atrial system with a trans-septal component deployed within the left atrium - e.g., the systems 40 shown in Figs. 31 to 32 or the implants 10 shown in Figs. 10 to 19 -- can also include right heart components 54 placed within or tethered to the SVC or  
35 IVC, which anchor the intra-atrial components relative to



- 52 -

the tissue consolidating component.

**A. Right Atrial Septal Brace**

In embodiment shown in Fig. 33A, the right heart component 54 includes a septum brace bar 56 that is coupled to the septal anchor 52. As illustrated, the brace bar 56 desirably extends superiorly and inferiorly along the septum from the anchor 52, to distribute forces uniformly along the septum. A brace bar 56 of the type shown in Fig. 33A can also be coupled in the same fashion to the anchor 20, when used in combination with the implant 10 shown in Fig. 10.

As Fig. 33A also shows, the right heart components 54 may also include stents 58 placed either in the inferior vena cava (IVC), superior vena cava (SVC), or coronary sinus (CS), or the right atrium in general, which are coupled to the brace bar 56. The right heart stents 58 serve as braces to further disperse and absorb forces from the lifting component into the right heart.

**B. Vena Caval Anchoring**

As Figs. 33B and 33C show, a given intra-atrial bridging component (e.g., implant 10 in Fig. 10 or component 44 in Fig. 31) can be coupled or tethered directly to anchors or stents 58 deployed in either the SVC or IVC. In this arrangement, the intra-atrial bridging component is not anchored to the septum, but rather can pass through the septum (e.g., at the fossa ovalis) directly to the anchoring stent 58. A washer 200 may be provided on the septum that permits the bridging component to pass through the septum without tearing, but does not anchor the component. Instead, an element 202, e.g., a cable or memory shaped alloy or tether 202, couples the bridging component to the stent 58, which serves to anchor the bridging component.

In the embodiment shown in Fig. 33B, the washer 200 is located high on the fossa ovalis, and the element 202

- 53 -

is coupled to a stent 58 in the SVC. It is believed that this arrangement maximizes the magnitude of the upward lifting (vertical) vector generated by the bridging component BC on the tissue-consolidating component 42 in the great cardiac vein.

In the embodiment shown in Fig. 33C, the washer 200 is located low on the fossa ovalis, and the element 202 is coupled to a stent 58 in the IVC. It is believed that this arrangement maximizes the magnitude of the horizontal vector generated by the bridging component BC on the tissue-consolidating component 42 in the great cardiac vein.

#### C. Implantation

The right heart components 54 described above lend themselves to implantation in any of the manners previously described.

In a representative catheter-based embodiment, the tissue-consolidating component 42 (which can comprise, e.g., a rigid, malleable, radiopaque-marked stent dilated to 10 mm to 25 mm in diameter) can be placed by a catheter into the great cardiac vein, as before described. If the bracing stent 58 is intended to rest in the IVC, a femoral vein into the IVC route can be used. If the bracing stent 58 is intended to rest in the SVC, then a jugular vein into the SVC route is selected.

A guide sheath is then placed through a femoral vein-IVC-fossa ovalis route across the left atrium to the tissue-consolidating component 42. The element 202 is passed through the guide sheath. The element 202 carries at its distal end a grasper (which can be sized, e.g., 7 French). The grasper grasps onto a strut of the tissue consolidating stent 42 and locks that grasp. The element 202 is then drawn across the left atrium, through the fossa ovalis. Tension is applied from within the right atrium to pull the tissue-consolidating stent 42 up and

- 54 -

in inside the left atrium. The tension is set to moderate or eliminate the functional MR as much as possible.

The caval stent 58 (e.g., measuring 5cm to 10 cm long, and 3cm to 7cm diameter) is threaded over the  
5 element 202 into the vena cava where catheter access for the element 202 was achieved. In the IVC, for example, the stent 58 gets placed just above the liver and just below the right atrium. A lock device is threaded over the element 202 from its proximal end up to the caval  
10 stent 58. The element 202 is then cut below the lock nut and the element 202 below the nut is removed. The stent 58 serves to hold and lock the element 202 in its vertical position.

It is believed that providing the option of using  
15 either the atrial septum, and/or the IVC, and/or the SVC as potential anchoring sites in the manners just described, makes it possible to flexibly adapt a given implant system to the local anatomy encountered, as well as to optimally guide and distribute the direction and  
20 magnitude of the force vectors sought to be applied by the intra-atrial bridging component or components.

### III. Circumferential Implant Systems

#### A. Circumferential Loop

##### 1. Structure

25 Fig. 35 shows a loop implant system 70 for treating mitral regurgitation that applies, either alone or in conjunction with other force vectors, a circumferential force vector upon tissue in the region of the posterior mitral valve annulus. The inward radial force vector  
30 compresses the posterior annulus with a sphincter-like effect, as well as toward to septum, reducing dilation.

As shown in Fig. 35, the system 70 includes an elongated implant 72 having first and second anchoring regions 74 and 76, and an intermediate region 78  
35 extending between them. In total length, the implant 72

- 55 -

is sized and configured to be deployed as a loop, which  
(i) extends from the first anchoring region 74 on the  
interatrial septum in the right atrium or in a vena cava,  
(ii) passes within the right atrium through the coronary  
5 sinus and, from there, the intermediate region 78 resides  
within the great cardiac vein parallel and superior to  
the posterior mitral annulus, (iii) exits the great  
cardiac vein through a sidewall of a stent or midrange of  
a T-shaped tubular device, an end of a stent or tubular  
10 anchor device located inside the great coronary vein, and  
then through the adjacent inner wall of atrial tissue at  
or near the region of the lateral trigone, (iv) from  
there, extends in a posterior-to-anterior direction  
across the left atrium, through the interatrial septum  
15 into the right atrium, and (v) allows the second  
anchoring region 76 to be anchored in the right atrium or  
in a vena cava coincident with or near the first  
anchoring region 74. One or more anchors 80 hold the loop  
implant 72 in tension.

20 As shown in Fig. 35, the anchoring site for the  
anchor 80 is shown to be superior to the plane of the  
anterior mitral valve annulus. More particularly, the  
anchoring site for the anchor 80 is within the fossa  
ovalis. This is because the fossa ovalis presents a  
25 fibrous tissue region that can be accessed and fastened  
to with relative technical ease, given conventional  
interventional radiological and surgical skills and  
techniques. It should be appreciated other more inferior  
or more superior sites can be used as trans-septal points  
30 of passage to optimize bridging element vectors in the  
septum, taking into account the same technical and  
surgical considerations.

The loop implant 70 serves to apply a direct  
mechanical force that pulls radially inward upon the  
35 posterior annulus. The direct mechanical force can serve

- 56 -

to shorten the minor axis of the annulus. In doing so, the implant 70 can also reactively reshape the annulus along its major axis and/or reactively reshape other surrounding anatomic structures. It should be appreciated, however, the presence of the implant 70 can serve to stabilize tissue adjacent the heart valve annulus, especially at different and important times in the cardiac cycle when valve coaptation should be improved (e.g., late diastole and early systole), without affecting the length of the minor or major axes. The mechanical force applied by the implant 70 to the tissues attached to the annulus can restore to the heart valve annulus and leaflets a more normal anatomic shape and tension, conducive to coaptation of the leaflets during ventricular systole. The implant 70 can thus reduce the incidence of mitral regurgitation.

Due to the superior location of the anchor 80 in the septum in the illustrated embodiment, the mechanical force of the loop implant 70 also pulls upward (i.e., with a vertical force vector) on the posterior annulus. This vertical vector is further enhanced when anchorage originates in the superior vena cava and a more vertical pull is exerted on the bridging element or bridge from this vantage than can be from a septal anchor. This vertical force vector can also serve to unload tension on the annulus, as well as to lessen the horizontal leading length of atrial tissue between the GCV and the ventricle, which must be moved by an anchor in the GCV in order to achieve any compressive effect on the posterior annulus, with the beneficial effects previously described. In situations where the SVC orifice is high enough, the magnitude of the vertical vector can be enhanced if the right side bridging element is anchored to a stent in the SVC in the manner shown in Fig. 33B, instead of to the septal wall itself. The loop implant 70

- 57 -

can also be anchored to a stent in the IVC in the manner shown in Fig. 33C, where in select situations the inverse may apply to the case of the SVC application.

In its most basic form, the implant 70 is made from  
5 a biocompatible metallic or polymer material, or a metallic or polymer material that is suitably coated, impregnated, or otherwise treated with a material to impart biocompatibility, or a combination of such materials. The material is also desirably radio-opaque or  
10 incorporates radio-opaque features to facilitate fluoroscopic visualization.

As shown in the illustrated embodiment, the portion of the intermediate region 78 that resides within the great cardiac vein can comprise a stent-like structure  
15 that is sized and configured to be introduced into the great cardiac vein through the coronary sinus os in the right atrium. In this form, the intermediate region 78 can comprise an expandable scaffold, which can take the form of a self-expanding stent, or a malleable structure  
20 that is expanded by means of an interior force, e.g., a balloon. The intermediate region 78 may be held in position within the vein by gripping the surrounding vessel wall, e.g., by barbs, tines, or the like. If desired, the intermediate region 78 may be further  
25 secured by suture, adhesive, or like material within the vein. The intermediate region 78 can incorporate roughened or porous surfaces and/or other materials (e.g., polyester fabric) to promote tissue in-growth.

The anchoring regions 74 and 76 can comprise wire-  
30 form structures formed by bending, shaping, joining, machining, molding, or extrusion of a metallic or polymer wire form structure to the intermediate region 78. Desirably, the material of the implant 70 is selected to impart elastic mechanical properties.

35                   2.     **Implantation**

- 58 -

The loop implant 70, like the implant or implant systems already described, lends itself to implantation in a heart valve annulus in a beating heart or an open heart surgical procedure, or by catheter-based technology  
5 via a peripheral venous access site under image guidance, or by closed chest thoracoscopic means through the chest, or by means of other open chest surgical access through the right atrium under image guidance.

For example, if a percutaneous, catheter-based  
10 procedure is used under image guidance, percutaneous vascular access can be achieved by conventional methods into the femoral or jugular or subclavian vein to deploy a first catheter 82 into the right atrium. As shown in Fig. 36, the first catheter 82 advances the implant 70,  
15 anchoring region 76 first, through the coronary sinus or in the right atrium and into the great cardiac vein. The anchoring region 76 and intermediate region 78 are advanced into the great cardiac vein, such that the anchoring region 76 is located at or near the lateral  
20 trigone. Fig. 36 shows access through the femoral-IVC route for purposes of illustration.

As Fig. 37 shows, a second catheter 84 is steered through the vasculature (also via the IVC) into the right atrium. The second catheter 84 carries a distal needle  
25 (not shown), which is deployed to pierce the septum between the right and left atrium (e.g., at the fossa ovalis). Once access between the right and left atriums is opened, a guide wire 32 is advanced trans-septally through the needle catheter 84 into the left atrium.

30 The second catheter 84 is withdrawn (see Fig. 38), and, under image guidance, a third catheter 86 is advanced over the guide wire 32 trans-septally through the fossa ovalis puncture, and into the left atrium. Under image guidance, the third catheter 86 is directed  
35 to the site where the anchoring region 76 resides within

- 59 -

the great cardiac vein. As before described, the catheter 86 can include an on-board distal steering mechanism or a magnetic tracking system to locate the targeted site. The third catheter 86 is manipulated to puncture atrial tissue at the targeted site, grip the anchoring region 76, and attach a bridging anchoring element 76 to or draw the anchoring region 76 out of the great cardiac vein and anteriorly across the left atrium (as Fig. 38 shows). The remaining portion of the intermediate region 78 is deployed from the first catheter 82 into the great cardiac vein, as the third catheter 86 leads the anchoring region 76 back through the septum and into the right atrium (as Fig. 39 shows).

The first catheter 82 and the third catheter 86 are manipulated within the right atrium to pull tension on the implant 70, until a lessening or elimination of the incidence of mitral regurgitation is confirmed by monitoring. Once the desired therapeutic result is achieved, the anchor 80 is applied to both anchoring regions 74 and 76, e.g., by one of the catheters 82 or 86 or by a separate intravascular crimping tool or a lock that is advanced from the outside over the wire to engage the brace. This retains the loop implant 70 in the desired degree of tension. The anchoring region 74 is cut next to anchor 80, ending the installation, and the intravascular tool or tools are withdrawn, leaving the implant 70 in the condition shown in Fig. 35.

#### B. Loop Systems

In an alternative embodiment (see Fig. 40), a loop implant system 90 includes a preformed shaped, cannulated structure 92 that is sized and configured to reside within the great cardiac vein. The structure 92 includes an interior lumen 94. The structure 92 is preformed to impart a shape-altering force upon tissue in the region of the great cardiac vein to counteract dilation of the



- 60 -

annulus. The structure 92 can comprise an expandable stent-like structure or a preformed tubular structure.

The implant system 90 also includes a tension element 96. The tension element 96 has anchoring end regions 98 and 100 and an intermediate region 102. The tension element 96 can comprise a wire-form structure formed by bending, shaping, joining, machining, molding, or extrusion of a metallic or polymer wire form structure. Desirably, the material of the element 96 is selected to impart elastic mechanical properties.

In use, as Fig. 40 shows, the end regions 98 and 100 are anchored to the interatrial septum by one or more anchors 104. In the illustrated embodiment, anchors 104 are affixed to the septum in the right and left heart.

Held in tension by the anchors 100, the intermediate region 102 of the element 96 extends within the right atrium from the end region 98, into the great cardiac vein through the coronary sinus, passes through the lumen 94 of the shaped structure 92 within the great cardiac vein, exits the great cardiac vein at or near the lateral trigone (or at any point thought to best achieve a maximal effect on the annulus to ameliorate functional mitral regurgitation - i.e., at or near the mid point of the posterior mitral annulus), and, from there, spans in a posterior-to-anterior path across the left atrium to the anchoring element 100.

Like the loop implant 70 shown in Fig. 35, the loop implant system 90 shown in Fig. 40 serves to apply a direct mechanical force that pulls radially inward upon the posterior annulus. The memory of the preshaped structure 92 amplifies the inward radial vector of the direct mechanical force adjacent the posterior annulus. As explained in connection with the implant 70, the force exerted by the implant system 90 can serve to restore the heart valve annulus and leaflets a more normal anatomic

- 61 -

shape and tension, conducive to coaptation of the leaflets during ventricular systole.

As previously explained in connection with the implant 70, the anchors 104 can be placed relatively high in the septum (e.g., at the fossa ovalis) to apply a mechanical force that also pulls upward (i.e., with a vertical force vector) on the posterior annulus. This vertical force vector can also serve to unload tension on the annulus, as well as to lessen the horizontal leading length of atrial tissue between the great cardiac vein and the ventricle, which must be moved by an anchor in the great cardiac vein into order to achieve a compressive effect on the posterior annulus. Alternatively, the implant can be anchored directly either to the SVC (in the manner shown in Fig. 33B) or to the IVC (in the manner shown in Fig. 33C).

Similar tools and techniques as previously described can be used to implant the system 90 shown in Fig. 40 using percutaneous, catheter-based procedures.

#### IV. Right Heart Implant Systems

##### A. Elastic Right Heart Implant

Fig. 41 shows an elastic right heart implant sized and configured to rest in compression in the right atrium (see Fig. 42) to affect the shape and/or function of a mitral valve annulus in the left atrium (see Fig. 43).

In terms of structure, the right heart implant 120 can be of the type described in copending United States Patent Application Serial No. 10/677,104, filed October 1, 2003, and entitled "Devices, Systems, and Methods for Reshaping a Heart Valve Annulus," which is incorporated herein by reference -- except that, in use, the implant 120 is intended, in use, to be implanted in the right heart and not the left heart, as disclosed in the referenced application.

- 62 -

As described in the above-identified application, the implant 120 is desirably made -- e.g., by bending, shaping, joining, machining, molding, or extrusion -- from a biocompatible, super-elastic metallic material. As shown in Fig. 41, the right heart implant 120 includes a pair of struts 122 and 124 joined by an intermediate rail 126.

As Figs. 42 and 43 show, the strut 122 is sized and configured to rest in tissue in, at, or near the septum in the right atrium at a location that is generally in opposition to a portion of the anterior annulus of the mitral valve in the left atrium (with the aorta in between). The other strut 124 is sized and configured to rest in tissue in, at, or near a right atrial wall which generally faces the location of the septal strut 122.

The superelastic material of the right heart implant 120 is selected to possess a desired spring constant. The spring constant imparts to the rail 126 the ability to be elastically compressed into an elastically loaded condition, when resting in engagement with tissue as just described. When in its elastically loaded, compressed condition, the rail 126 exerts opposing forces to the tissues through the struts 122 and 124.

The struts 122 and 124 can engage tissue in a stable fashion in various ways. The struts 122 and 124 can rely upon compressive forces imparted by the mechanical, superelastic properties of the rail 126 to retain a stable position engaged in tissue. The struts 122 and 124 can, alternatively or in combination with compressive forces, include barbs or other fixation devices that penetrate or otherwise take purchase in tissue. Other types of tissue engaging mechanisms can be used, e.g., roughened surfaces or tissue in-growth promoting materials. Any fixation mechanism may, if desired, be combined with suture, an adhesive, or like material to

- 63 -

further secure the right heart implant 120.

The compression force applied by the septal strut 122 applies a force on the septum in the direction of the left atrium (as shown by arrows in Fig. 43). The trans-septal force applied by the implant 120 may tend to displace tissue adjacent the anterior annulus of the mitral valve inwardly toward the posterior annulus (see Fig. 43). The trans-septal tissue displacement adjacent the anterior annulus may serve to shorten the minor axis of the mitral valve annulus (see Fig. 43). In doing so, the right heart implant 120 may also reactively reshape the mitral valve annulus along its major axis and/or reactively reshape other surrounding anatomic structures in the left heart. It should be appreciated, however, the presence of the right heart implant 120 may serve to stabilize tissue adjacent the mitral valve annulus, without affecting the length of its minor or major axes. The mechanical force applied by the right heart implant 120 across the septum may restore to the mitral valve annulus and leaflets a more normal anatomic shape and tension. The more normal anatomic shape and tension are conducive to coaptation of the leaflets during ventricular systole, which, in turn, reduces mitral regurgitation.

The right heart implant 120 can be elastically straightened and/or folded to fit within a catheter or sheath for deployment in a catheter-based procedure within the right atrium. Alternatively, the right heart implant 120 can be deployed during an open surgical or thoracoscopic procedure.

#### **B. Plastically Deformable Right Heart Implant**

Figs. 44A and 44B show a representative embodiment of a plastically deformable implant 130 sized and configured to rest in an expanded condition in compression against the septum in the right atrium (see

- 64 -

Fig. 48) to affect the shape and/or function of a mitral valve annulus in the left atrium (see Fig. 49).

As shown in Figs. 44A and 44B, the implant 130 includes a frame 132, which is shown to be generally oval or elliptical in configuration. Other linear or curvilinear configurations can be used. The frame may be made, e.g., by bending, shaping, joining, machining, molding, or extrusion a biocompatible, metallic or polymeric material.

10 The frame 132 is sized and configured to rest in tissue in, at, or near the septum in the right atrium at a location that is generally in opposition to a portion of the anterior annulus of the mitral valve in the left atrium.

15 The implant 130 also includes an array of tissue fixation elements 134, which are attached to the periphery of the frame 132. In the illustrated embodiment, the fixation elements 134 comprise barbs that penetrate tissue, to secure the frame 132 to the targeted tissue region. Other types of tissue engaging mechanisms can be used, e.g., roughened surfaces or tissue in-growth promoting materials. Any fixation mechanism may, if desired, be combined with suture, an adhesive, or like material to further secure the frame 132 of the right heart implant 130.

20 A plastically deformable structure 136 is mounted to the interior of the frame 132. In the illustrated embodiment, the structure 136 takes the form of a woven or mesh-like web, which can be made of a metallic or polymeric material. The structure 136 is attached to the frame 130 in a normally unstretched condition. In is in this condition that the implant 130 is affixed to the targeted tissue region on the septum (see Figs. 45 and 46). The right heart implant 130 can be elastically straightened and/or folded to fit within a catheter or

- 65 -

sheath for deployment in a catheter-based procedure within the right atrium. Alternatively, the right heart implant 130 can be deployed during an open surgical or thoracoscopic procedure.

5       The plastically deformable nature of the structure 136 makes possible its expansion and shaping *in situ* against the septum within the right atrium. As Fig. 47 shows, an inflatable body 138 (e.g., balloon) can be used to expand and shape the structure 136, as can a suitable  
10   mechanical device (e.g., a scissor-jack). The body 138 can be carried by a catheter 139 for deployment in a catheter-based procedure within the right atrium. Alternatively, the body 138 can be deployed during an open surgical or thoracoscopic procedure.

15       During expansion and shaping, the structure 136 is stretched into an outwardly bowed or concave configuration within the frame 130. The stretched structure 132 projects against the septum (see Figs. 48 and 49), applying a compression force across the septum.  
20   The compression force applied by the plastically deformed structure 136 is translated from the right heart side of the septum, across the septum, and to the anterior annulus of the mitral valve on the left heart side of the septum, where it may tend to displace tissue adjacent the  
25   anterior annulus of the mitral valve inwardly toward the posterior annulus (see Figs. 48 and 49). As before explained, the trans-septal tissue displacement adjacent the anterior annulus may serve to shorten the minor axis of the mitral valve annulus (see Fig. 49). In doing so,  
30   the right heart implant 130 may also reactively reshape the mitral valve annulus along its major axis and/or reactively reshape other surrounding anatomic structures in the left heart. It should be appreciated, however, the presence of the right heart implant 130 may serve to  
35   stabilize tissue adjacent the mitral valve annulus,

66 -

without affecting the length of its minor or major axes. The mechanical force applied by the right heart implant 130 across the septum may restore to the mitral valve annulus and leaflets a more normal anatomic shape and tension. The more normal anatomic shape and tension are conducive to coaptation of the leaflets during ventricular systole, which, in turn, reduces mitral regurgitation.

The plastically deformable implant 130 shown in Figs. 44A and 44B may also be used in association with a loop implant system 90 shown in Fig. 40. In this arrangement, the loop implant system 90 would include a linking member coupling the anchor 100 in the fossa ovalis to the plastically deformable implant 130 deployed in the right atrium in the position shown in Fig. 45. The plastically deformable implant 130 and linking member would serve as a stabilizing element for the anchor 100 and thus for the entire the loop implant system 90.

#### C. Right Heart Anchored Great Cardiac Vein

##### Implant

In preceding embodiments (see, e.g., Fig. 10 or Fig. 31), various implants 18 and 42 have been placed within the great cardiac vein, to serve as an attachment point for other intra-atrial components, which are placed in tension in the left atrium. As Fig. 50 shows, a given implant 140 can be placed into tension within the great cardiac vein, and the tension can be retained by an anchor 142 affixed to the septum within the right atrium. The tension tends to pull a radially shaped and rigid anchor 140 along with the posterior annulus in a radially inward direction. The great cardiac vein implant 140, placed into tension and anchored in the right atrium, can be used alone, or in combination with other components deployed within the left atrium. The implant 140 can comprise a stent-like structure (as shown) or a pre-

- 67 -

formed rod (e.g., c-shaped) placed in the great coronary vein.

As Fig. 51 shows, the great cardiac vein implant 140, placed into tension and anchored in the right atrium, can also be used in combination with one or more components deployed within the right atrium. In the illustrated embodiment, an appendage 144 coupled to the anchor 142 extends from the anchor 142 in a superior to inferior direction. The appendage 144 includes a projection 146 that is sized and configured to rest in compression against tissue in, at, or near the septum in the right atrium at a location that is generally in opposition to a portion of the anterior annulus of the mitral valve in the left atrium. The compression force applied by the projection 146 is translated from the right heart side of the septum in relative position within the heart in total, septially across the septum in relation to the anterior annulus of the mitral valve on the left heart side of the septum, where it tends to orient vectors of the implant along the anterior annulus of the mitral valve inwardly toward the posterior annulus, as Fig. 51 shows. It thus has the equivalent therapeutic effect upon the mitral valve annulus imparted by the right heart implants 120 and 130 previously described, working in combination with the tension force applied by the right heart-anchored great cardiac vein implant 140.

As Fig. 52 shows, the great cardiac vein implant 140, placed into tension and anchored in the right atrium, and further augmented by the appendage 144 with its projection 146, can be used in combination with one or more other components 148 deployed within the left atrium. As Fig. 52 shows, the other components 148 can themselves comprise trans-septal components that are anchored to the great cardiac vein implant 140, as well



- 68 -

as the septum, joined by a common anchor 142. In this arrangement, the components 148 apply horizontal pulling and/or vertical lifting forces upon the posterior mitral valve annulus in manner previously described, working in  
5 combination with the tension force applied by the right heart-anchored great cardiac vein implant 140, as well as the compression force applied by the projection 146.

It should by now be apparent that the features and concepts disclosed herein can be used, alone or in  
10 combination, to create implants or systems of implants that apply a selected force vector or a selected combination of force vectors, which allow mitral valve leaflets to better coapt. The features and concepts make possible rapid deployment, facile endovascular delivery,  
15 and full intra-atrial retrievability. The features and concepts also make use of strong fluoroscopic landmarks.

While the new devices and methods have been more specifically described in the context of the treatment of a mitral heart valve, it should be understood that other  
20 heart valve types can be treated in the same or equivalent fashion. By way of example, and not by limitation, the present systems and methods could be used to prevent or reduce retrograde flow in any heart valve annulus, including the tricuspid valve, the pulmonary  
25 valve, or the aortic valve. In addition, other embodiments and uses of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. The specification and examples should be  
30 considered exemplary and merely descriptive of key technical features and principles, and are not meant to be limiting. The true scope and spirit of the invention are defined by the following claims. As will be easily understood by those of ordinary skill in the art,  
35 variations and modifications of each of the disclosed

- 69 -

embodiments can be easily made within the scope of this invention as defined by the following claims.

- 70 -

What is claimed is:

1. An implant system to treat a mitral heart valve comprising
  - a posterior anchor structure sized and configured to extend within the great cardiac vein adjacent a posterior annulus of the mitral valve,
    - at least one implant sized and configured to extend across a left atrium including a posterior anchoring region sized and configured to extend from the left atrium into the great cardiac vein and couple to the posterior anchor structure within the great cardiac vein, an anterior anchoring region sized and configured to extend from the left atrium through an interatrial septum and into a right atrium, and a bridging region between the posterior and anterior anchoring regions sized and configured to span the left atrium in a posterior-to-anterior direction, and
    - an anterior anchor structure sized and configured to couple to the anterior anchoring region in or near the right atrium to hold in tension the bridging element between the posterior and anterior anchoring regions.
2. An implant system according to claim 1 wherein the posterior anchor structure comprises a structure separate from the implant to which the posterior anchoring region is joined.
3. An implant system according to claim 1 wherein the posterior anchor structure comprises a structure integrally joined to the posterior anchoring region.
4. An implant system according to claim 1 wherein the posterior anchor structure comprises a stent-like structure.
5. An implant system according to claim 1 wherein the posterior anchor structure

- 71 -

comprises, at least in part, a radiopaque structure.

6. An implant system according to claim 1  
wherein the posterior anchor structure  
comprises a structure having, when deployed, an outside  
5 diameter of between about 0.5 mm and about 30 mm.

7. An implant system according to claim 1  
wherein the posterior anchor structure  
comprises a structure having, when deployed, an outside  
diameter of between about 10 mm and about 20 mm.

10 8. An implant system according to claim 1  
wherein the posterior anchor structure  
includes a magnetic or ferromagnetic material.

9. An implant system according to claim 1  
wherein the posterior anchor structure  
15 includes at least one anchoring site sized and configured  
to accommodate attachment of the posterior anchoring  
region.

10. An implant system according to claim 9  
wherein the at least one anchoring site  
20 includes a magnetic or ferromagnetic material.

11. An implant system according to claim 1  
wherein the posterior anchor structure  
includes at least one anchoring site sized and configured  
to accommodate attachment of the posterior anchoring  
25 region, and a region extending either medially from the  
anchoring site, or laterally from the anchoring site, or  
both medially or laterally from the anchoring site, to  
consolidate the great cardiac vein.

12. An implant system according to claim 1  
30 wherein the posterior anchor structure  
comprises a rigid material, or a semi-rigid material, or  
a flexible material, or a porous material, or  
combinations thereof.

13. An implant system according to claim 1  
35 wherein the posterior anchor structure

- 72 -

includes one or more components to engage tissue within the great cardiac vein.

14. An implant system according to claim 1  
wherein the posterior anchoring region  
5 includes means for mechanically engaging at least a portion of the posterior anchoring structure within the great cardiac vein.

15. An implant system according to claim 1  
wherein the posterior anchoring region  
10 includes a hook-like structure for engaging at least a portion of the posterior anchoring structure within the great cardiac vein.

16. An implant system according to claim 1  
wherein the posterior anchoring region  
15 includes a cross-bar structure for engaging at least a portion of the posterior anchoring structure within the great cardiac vein.

17. An implant system according to claim 1  
wherein the posterior anchoring region  
20 includes a grasper for engaging at least a portion of the posterior anchoring structure within the great cardiac vein.

18. An implant system according to claim 1  
wherein the posterior anchoring region  
25 includes a cross-bar structure integrally joined to the posterior anchoring region of the implant for deployment within the great cardiac vein.

19. An implant system according to claim 1  
wherein the posterior anchoring region  
30 includes a magnetic or ferromagnetic material.

20. An implant system according to claim 19  
wherein the posterior anchor structure  
includes at least one anchoring site sized and configured  
to accommodate attachment of the posterior anchoring  
35 region, the at least one anchoring site including a

- 73 -

material magnetically attracted to the magnetic or ferromagnetic material on the posterior anchoring region.

21. An implant system according to claim 1  
wherein the anterior anchoring structure is  
5 sized and configured for attachment on the interatrial septum.

22. An implant system according to claim 1  
wherein the anterior anchoring structure is  
sized and configured for attachment on the interatrial  
10 septum in a region at or near of the fossa ovalis.

23. An implant system according to claim 1  
wherein the anterior anchoring structure is  
sized and configured for attachment within the superior  
vena cava.

15 24. An implant system according to claim 1  
wherein the anterior anchoring structure  
comprises a stent-like structure sized and configured for  
attachment within the superior vena cava.

25 25. An implant system according to claim 1  
wherein the anterior anchoring structure is  
sized and configured for attachment within the superior  
vena cava, and further including a pass-through element  
on the interatrial septum through which the anterior  
anchoring region extends without anchoring to the  
25 interatrial septum.

26. An implant system according to claim 1  
wherein the anterior anchoring structure is  
sized and configured for attachment within the inferior  
vena cava.

30 27. An implant system according to claim 1  
wherein the anterior anchoring structure  
comprises a stent-like structure sized and configured for  
attachment within the inferior vena cava.

28. An implant system according to claim 1  
35 wherein the anterior anchoring structure is

- 74 -

5 sized and configured for attachment within the inferior vena cava, and further including a pass-through element on the interatrial septum through which the anterior anchoring region extends without anchoring to the interatrial septum.

29. An implant system according to claim 1 wherein the anterior anchoring structure is sized and configured for attachment within the superior vena cava and the inferior vena cava.

10 30. An implant system according to claim 1 wherein the anterior anchoring structure comprises a stent-like structure sized and configured for attachment within the superior vena cava and the inferior vena cava.

15 31. An implant system according to claim 1 wherein the anterior anchoring structure is sized and configured for attachment within the inferior vena cava and the superior vena cava, and further including a pass-through element on the interatrial  
20 septum through which the anterior anchoring region extends without anchoring to the interatrial septum.

32. An implant system according to claim 1 wherein the anterior anchoring structure is sized and configured for attachment within the inferior  
25 vena cava, the superior vena cava, and the interatrial septum.

33. An implant system according to claim 1 wherein the bridging region is sized and configured to extend in a posterior-to-anterior direction  
30 within the left atrium in a generally straight path.

34. An implant system according to claim 1 wherein the bridging region is sized and configured to extend in a posterior-to-anterior direction within the left atrium in a medially or laterally curved  
35 path toward a trigone of the mitral valve.

- 75 -

35. An implant system according to claim 1  
wherein the bridging region is sized and  
configured to extend in a posterior-to-anterior direction  
within the left atrium in a superior path toward the dome  
5 of the left atrium.

36. An implant system according to claim 1  
wherein the bridging region is sized and  
configured to extend in a posterior-to-anterior direction  
within the left atrium in an inferiorly path toward the  
10 mitral valve.

37. An implant system according to claim 1  
wherein the bridging region comprises an  
elastic structure, or an inelastic structure, or  
combinations thereof.

15 38. An implant system according to claim 1  
wherein the bridging region comprises a wire-  
form structure.

39. An implant system according to claim 1  
wherein the bridging region comprises a  
20 suture.

40. An implant system according to claim 1  
wherein the bridging region is collapsible for  
placement within a catheter.

41. An implant system according to claim 1  
25 wherein the posterior anchor structure is  
collapsible for placement within a catheter.

42. An implant system according to claim 1  
wherein more than one implant comprising an  
anterior anchoring region, and anterior anchoring region,  
30 and a bridging region as defined in claim 1 is included.

43. A method of treating a mitral heart valve  
annulus comprising providing an implant system as defined  
in claim 1, installing the posterior anchor structure,  
the implant, and the anterior anchor structure.

35 44. A method according to claim 43



- 76 -

wherein the installing step includes installing the posterior anchor structure within the great cardiac vein and coupling the posterior anchoring region of the implant to the posterior anchor structure  
5 within the great cardiac vein.

45. A method according to claim 44

wherein the step of installing the posterior anchor structure includes deploying the posterior anchor structure from the right atrium through the coronary  
10 sinus.

46. A method according to claim 43

wherein the step of installing the posterior anchor structure includes installing the posterior anchor structure within the great cardiac vein prior to  
15 installing the implant to induce fibrosis before installing the implant.

47. A method according to claim 43

wherein the step of installing the posterior anchor structure includes deploying the posterior anchor structure from the left atrium through a wall of the  
20 great cardiac vein.

48. A method according to claim 43

wherein the step of installing the implant includes extending the bridging region in a posterior-to-  
25 anterior direction across the left atrium and extending the anterior anchoring region across the interatrial septum into the right atrium

49. A method according to claim 43

wherein the step of installing the implant includes placing the bridging region in tension between  
30 the posterior and anterior anchoring regions.

50. A method according to claim 49

wherein the step of installing the implant includes coupling the anterior anchor structure to the  
35 anterior anchoring region to hold the tension.

- 77 -

51. A method according to claim 43  
wherein the step of installing the anterior anchor structure comprises placing the anterior anchor structure on the interatrial septum.
- 5 52. A method according to claim 51  
wherein the anterior anchor structure is placed at or near a fossa ovalis.
53. A method according to claim 43  
wherein the step of installing the anterior anchor structure comprises placing the anterior anchor structure in the superior vena cava.
- 10 54. A method according to claim 43  
wherein the step of installing the anterior anchor structure comprises placing the anterior anchor structure in the inferior vena cava.
- 15 55. A method according to claim 43  
wherein the step of installing the anterior anchor structure comprises placing an anterior anchor structure in the inferior vena cava and the superior vena cava.
- 20 56. A method according to claim 43  
wherein the step of installing the anterior anchor structure comprises placing an anterior anchor structure in the inferior vena cava, in the superior vena cava, and on the interatrial septum.
- 25 57. A method according to claim 43  
wherein the step of installing at least one of the posterior anchor structure, the implant, and the anterior anchor structure comprises use of a catheter. \$\$
- 30 58. An implant system to treat a mitral heart valve comprising  
a tissue consolidating component sized and configured to extend within the great cardiac vein and to consolidate the great cardiac vein into a unified physical structure adjacent a length comprising at least
- 35

- 78 -

a portion of a posterior annulus of the mitral valve,

at least one implant sized and configured to extend across a left atrium including a posterior anchoring region sized and configured to extend from the left atrium into the great cardiac vein and couple to the tissue consolidating component within the great cardiac vein, an anterior anchoring region sized and configured to extend from the left atrium through an interatrial septum and into a right atrium, and a bridging region between the posterior and anterior anchoring regions sized and configured to span the left atrium in a posterior-to-anterior direction, the bridging region being configured to apply a force vector upon the tissue consolidating component when placed into tension between the posterior and anterior anchoring regions, and

an anterior anchor structure sized and configured to couple to the anterior anchoring region in or near the right atrium to hold in tension the bridging element between the posterior and anterior anchoring regions.

59. An implant system to treat a mitral heart valve comprising

bonding means for conjoining the great cardiac vein to the left ventricle in a tissue region between the great cardiac vein and the left ventricle,

at least one implant sized and configured to extend across a left atrium including a posterior anchoring region sized and configured to extend from the left atrium into the great cardiac vein and couple an anchor within the great cardiac vein, an anterior anchoring region sized and configured to extend from the left atrium through an interatrial septum and into a right atrium, and a bridging region between the posterior and anterior anchoring regions sized and configured to span the left atrium in a posterior-to-anterior

- 79 -

direction, the bridging region being configured to apply a force vector upon the great cardiac vein when placed into tension between the posterior and anterior anchoring regions, and

5           an anterior anchor structure sized and configured to couple to the anterior anchoring region in or near the right atrium to hold in tension the bridging element between the posterior and anterior anchoring regions, whereby the force vector is distributed by the  
10   conjoined tissue region to the left ventricle.

60.   An implant system to treat a mitral heart valve comprising

          a tissue consolidating component sized and configured to extend within the great cardiac vein and to  
15   consolidate the great cardiac vein into a unified physical structure along a length comprising at least a portion of a posterior annulus of the mitral valve,

          bonding means for conjoining the great cardiac vein to the left ventricle in a tissue region between the  
20   great cardiac vein and the left ventricle,

          at least one implant sized and configured to extend across a left atrium including a posterior anchoring region sized and configured to extend from the left atrium into the great cardiac vein and couple to the  
25   tissue consolidating component within the great cardiac vein, an anterior anchoring region sized and configured to extend from the left atrium through an interatrial septum and into a right atrium, and a bridging region between the posterior and anterior anchoring regions  
30   sized and configured to span the left atrium in a posterior-to-anterior direction, the bridging region being configured to apply a force vector upon the tissue consolidating component when placed into tension between the posterior and anterior anchoring regions, and

35           an anterior anchor structure sized and

- 80 -

configured to couple to the anterior anchoring region in or near the right atrium to hold in tension the bridging element between the posterior and anterior anchoring regions, whereby the force vector is distributed by the tissue consolidating component and the conjoined tissue region to the left ventricle.

61. An implant system according to claim 58 or 59 or 60

wherein the force vector includes a horizontal component to exert an inward force.

62. An implant system according to claim 58 or 59 or 60

wherein the force vector includes a vertical component to exert an upward lifting force.

63. An implant system according to claim 58 or 59 or 60

wherein the force vector includes horizontal and vertical components to exert both inward and upward lifting forces.

64. An implant system according to claim 58 or 59 or 60

wherein the force vector is greater than about forty-five degrees from horizontal.

65. An implant system according to claim 58 or 59 or 60

wherein the force vector is equal to or less than about forty-five degrees from horizontal.

66. An implant system according to claim 59 or 60 wherein the bonding means includes a fastener attached in the tissue region.

67. An implant system according to claim 59 or 60 wherein the bonding means includes drugs, and/or irritative agents, and/or heat, and/or chemical agents applied to the tissue region.

68. An implant system according to claim 59 or 60

- 81 -

wherein the bonding means includes tissue fibrosis induced in the tissue region.

69. An implant system according to claim 59 or 60 wherein the bonding means includes an array of  
5 magnets and/or soft ferromagnetic material.

70. An implant system according to claim 58 or 60 wherein the tissue consolidating component comprises a stent-like structure.

71. An implant system according to claim 58 or 60  
10 wherein the tissue consolidating component includes a cross-bar structure integrally joined to the posterior anchoring region of the implant for deployment within the great cardiac vein.

72. An implant system according to claim 58 or 60  
15 wherein the tissue consolidating component comprises, at least in part, a radiopaque structure.

73. An implant system according to claim 58 or 60 wherein the tissue consolidating component comprises a structure having an outside diameter, when  
20 deployed, of between about 0.5 mm and about 30 mm.

74. An implant system according to claim 58 or 60 wherein the tissue consolidating component comprises a structure having an outside diameter, when  
deployed, of between about 10 mm and about 20 mm.

75. An implant system according to claim 58 or 60  
25 wherein the tissue consolidating component includes a magnetic or ferromagnetic material.

76. An implant system according to claim 58 or 60 wherein the tissue consolidating element  
30 comprises a rigid material, or a semi-rigid material, or a flexible material, or a porous material, or combinations thereof.

77. An implant system according to claim 58 or 60 wherein the tissue consolidating component  
35 includes one or more components to engage tissue within

- 82 -

the great cardiac vein.

78. An implant system according to claim 58 or 60 wherein the posterior anchor structure includes means for engaging at least a portion of the tissue consolidating element within the great cardiac vein.

79. An implant system according to claim 58 or 60 wherein the posterior anchoring region is integrally connected to the tissue consolidating element.

80. An implant system according to claim 58 or 60 wherein the posterior anchoring region includes a hook-like structure for engaging at least a portion of the tissue consolidating component within the great cardiac vein.

81. An implant system according to claim 58 or 60 wherein the posterior anchoring region includes a cross-bar structure for engaging at least a portion of the tissue consolidating element within the great cardiac vein.

82. An implant system according to claim 58 or 60 wherein the posterior anchoring region includes a grasper for engaging at least a portion of the tissue consolidating component within the great cardiac vein.

83. An implant system according to claim 58 or 60 wherein the posterior anchoring region includes a magnetic or ferromagnetic material.

84. An implant system according to claim 83 wherein the tissue consolidating component includes at least one anchoring site sized and configured to accommodate attachment of the posterior anchoring region, the at least one anchoring site including a material magnetically attracted to the magnetic or ferromagnetic material on the posterior anchoring region.

85. An implant system according to claim 58 or 59

- 83 -

or 60

wherein the anterior anchoring structure is sized and configured for attachment on the interatrial septum.

- 5        86.    An implant system according to claim 85  
         wherein the anterior anchoring structure is sized and configured for attachment on the interatrial septum in a region at or near of a fossa ovalis.

87.    An implant system according to claim 58 or 59  
10    or 60

         wherein the anterior anchoring structure is sized and configured for attachment within the superior vena cava.

88.    An implant system according to claim 58 or 59  
15    or 60

         wherein the anterior anchoring structure is sized and configured for attachment within the inferior vena cava.

89.    An implant system according to claim 58 or 59  
20    or 60

         wherein the anterior anchoring structure is sized and configured for attachment within the superior vena cava and the inferior vena cava.

90.    An implant system according to claim 58 or 59  
25    or 60

         wherein the anterior anchoring structure is sized and configured for attachment within the superior vena cava, within the inferior vena cava, and on the interatrial septum.

- 30       91.    An implant system according to claim 58 or 59  
         or 60

         wherein the bridging region comprises an elastic structure, or an inelastic structure, or combinations thereof.

- 35       92.    An implant system according to claim 58 or 59



- 84 -

or 60

wherein the bridging region comprises a wire-form structure.

93. An implant system according to claim 58 or 59  
5 or 60

wherein the implant is collapsible for placement within a catheter.

94. An implant system according to claim 58 or 60  
10 wherein the tissue consolidating component is collapsible for placement within a catheter.

95. A method of treating a mitral heart valve comprising

consolidating the great cardiac vein into a unified physical structure adjacent a length comprising  
15 at least a portion of a posterior annulus of the mitral valve,

coupling a posterior region of an implant to the consolidated great cardiac vein,

20 extending the implant across the left atrium and through an interatrial septum and into a right atrium,

tensioning the implant to distribute a force vector to atrial tissue adjacent the posterior mitral valve annulus through the consolidated great cardiac  
25 vein, and

anchoring an anterior region of the implant to tissue in or near the right atrium to maintain the force vector.

96. A method of treating a mitral heart valve  
30 comprising

conjoining the great cardiac vein to a left ventricle in a tissue region between the great cardiac vein and the left ventricle,

35 coupling a posterior region of an implant to an anchor in the great cardiac vein,

- 85 -

extending the implant across the left atrium  
and through an interatrial septum and into a right  
atrium,

5        tensioning the implant to distribute a force  
vector to the left ventricle through the conjoined region  
of tissue, and

         anchoring an anterior region of the implant to  
tissue in or near the right atrium to maintain the force  
vector, whereby the force vector is distributed by the  
10      the conjoined tissue region to the left ventricle.

97.    A method of treating a mitral heart valve  
comprising

         consolidating the great cardiac vein into a  
unified physical structure adjacent a length comprising  
15      at least a portion of a posterior annulus of the mitral  
valve,

         conjoining the consolidated great cardiac vein  
to a left ventricle in a tissue region between the great  
cardiac vein and the left ventricle,

20      coupling a posterior region of an implant to  
the consolidated great cardiac vein,

         extending the implant across the left atrium  
and through an interatrial septum and into a right  
atrium,

25      tensioning the implant to distribute a force  
vector to the left ventricle through the consolidated  
great cardiac vein and conjoined region of tissue, and

         anchoring an anterior region of the implant to  
tissue in or near the right atrium to maintain the upward  
30      force vector, whereby the force vector is distributed by  
the consolidating great cardiac vein and the conjoined  
tissue region to the left ventricle.

98.    A method according to claim 95 or 96 or 97

         wherein the force vector includes a horizontal  
35      component to exert an inward force.

- 86 -

99. A method according to claim 95 or 96 or 97  
wherein the force vector includes a vertical  
component to exert an upward lifting force.

100. A method according to claim 95 or 96 or 97  
5 wherein the force vector includes horizontal  
and vertical components to exert both inward and upward  
lifting forces.

101. A method according to claim 95 or 96 or 97  
wherein the force vector is greater than about  
10 forty-five degrees from horizontal.

102. A method according to claim 95 or 96 or 97  
wherein the force vector is equal to or less  
than about forty-five degrees from horizontal.

103. A method according to claim 96 or 97  
15 wherein conjoining includes attaching a  
fastener to the tissue region.

104. A method according to claim 96 or 97  
wherein conjoining includes the application of  
drugs, and/or irritative agents, and/or heat, and/or  
20 chemical agents to the tissue region.

105. A method according to claim 96 or 97  
wherein conjoining includes inducing tissue  
fibrosis in the tissue region.

106. A method according to claim 96 or 97  
25 wherein conjoining includes implanting an  
array of magnets and/or soft ferromagnetic material in  
the great cardiac vein and the tissue region.

107. A method according to claim 95 or 97  
wherein the step of consolidating the great  
30 cardiac vein includes installing an elongated posterior  
anchor structure into the great cardiac vein.

108. A method according to claim 107  
wherein the step of installing includes  
installing the elongated posterior anchor from the right  
35 atrium through the coronary sinus.

- 87 -

109. A method according to claim 107  
wherein the step of coupling the posterior region of the implant to the consolidated great cardiac vein includes coupling the posterior region to at least a portion of the elongated posterior anchor.
110. A method according to claim 107  
wherein the step of installing includes installing the elongated posterior anchor from the left atrium through a wall of the great cardiac vein.
111. A method according to claim 107  
wherein the step of installing includes installing the elongated posterior anchor within the great cardiac vein prior to the coupling step to induce fibrosis before the coupling the posterior region of the implant to the elongated posterior anchor.
112. A method according to claim 95 or 96 or 97  
wherein the step of anchoring an anterior region of the implant to tissue in or near the right atrium includes anchoring the anterior region on an interatrial septum.
113. A method according to claim 112  
wherein the step of anchoring the anterior region on an interatrial septum includes anchoring the anterior region at or near a fossa ovalis.
114. A method according to claim 95 or 96 or 97  
wherein the step of anchoring the anterior region of the implant to tissue in or near the right atrium includes anchoring the anterior region in the superior vena cava.
115. A method according to claim 95 or 96 or 97  
wherein the step of anchoring an anterior region of the implant to tissue in or near the right atrium includes anchoring the anterior region in the inferior vena cava.
116. A method according to claim 95 or 96 or 97

- 88 -

wherein the step of anchoring an anterior region of the implant to tissue in or near the right atrium includes anchoring the anterior region in the inferior vena cava and the superior vena cava.

5       117. A method according to claim 95 or 96 or 97  
          wherein the step of anchoring an anterior region of the implant to tissue in or near the right atrium includes anchoring the anterior region in the inferior vena cava, in the superior vena cava, and on the  
10   interatrial septum.

          118. A method according to claim 95 or 96 or 97  
          wherein at least one of the steps of the method comprises using a catheter.

          119. An implant to treat a mitral heart valve  
15   comprising  
          an elongated structure sized and configured to be deployed as a loop including first and second end anchoring regions, each sized and configured, in use, to extend into the right atrium, and an intermediate region  
20   coupled to the first and second end anchoring regions sized and configured to extend outside the right atrium in a circumferential path within the great cardiac vein adjacent a posterior annulus of the mitral valve, and  
          an anchor sized and configured to couple to  
25   the first and second end anchoring regions in the right atrium or a vena cava to hold the intermediate region in tension.

          120. An implant according to claim 119  
          wherein the second end anchoring region is  
30   sized and configured to extend from the intermediate region within the great cardiac vein, across the left atrium in a posterior-to-anterior direction, and through the interatrial septum into the right atrium.

          121. An implant according to claim 119  
35   wherein the first end anchoring region is

- 89 -

sized and configured to extent from the intermediate region within the great cardiac vein through the coronary sinus into the right atrium.

122. A method of treating a mitral heart valve  
5 comprising

providing an implant as defined in claim 119,  
deploying the intermediate region through the coronary sinus into the great cardiac vein while retaining the first end anchoring region within the right  
10 atrium,

extending the second end anchoring region in a posterior-to-anterior direction across the left atrium and through the interatrial septum into the right atrium, applying tension to the intermediate region,

15 and

affixing the anchor to the first and second end anchoring regions in the right atrium or a vena cava to hold the intermediate region in tension.

123. An implant to treat a mitral heart valve  
20 comprising an elongated structure sized and configured to be deployed in tension a circumferential path within the great cardiac vein adjacent a posterior annulus of the mitral valve, the structure including an end anchoring region sized and configured to extent from the coronary  
25 sinus into the right atrium, and an anchor sized and configured to couple to the end anchoring region on the interatrial septum in the right atrium.

124. An implant according to claim 123  
further including a structure coupled to the  
30 anchor sized and configured to rest in the right atrium against the interatrial septum.

125. A method of treating a mitral heart valve comprising using the implant as defined in claim 123.

126. An implant system for use within a heart  
35 chamber comprising

- 90 -

a first implant sized and configured to rest within the heart vessel adjacent to a heart chamber, the first implant including an anchoring site,

5 a second implant sized and configured to be deployed, at least in part, within the heart chamber and including an anchoring region sized and configured to couple to the anchoring region of the first implant within the heart vessel, and

10 a magnetic or ferromagnetic material associated with the anchoring site of the first implant and the anchoring region of the second region to magnetically attract the anchoring region to the anchoring site.

127. An implant system for treating a mitral heart valve comprising

15 a first implant sized and configured to rest within the great cardiac vein adjacent a posterior annulus of the mitral valve, the first implant including an anchoring site,

20 a second implant sized and configured to be deployed, at least in part, within the left atrium and including an anchoring region sized and configured to couple to the anchoring region of the first implant within the great cardiac vein, and

25 a magnetic or ferromagnetic material associated with the anchoring site of the first implant and the anchoring region of the second region to magnetically attract the anchoring region to the anchoring site.

30 128. A method for deploying implants within a heart chamber comprising

deploying a first implant within a heart vessel adjacent to a heart chamber,


35 deploying a second implant within the heart chamber,

- 91 -

magnetically attracting a region of the second implant within the heart chamber to a region of the first implant within the heart vessel.

129. A method according to claim 128
- 5 further including the step of coupling the region of the second implant to the region of the first implant within the heart vessel.



*Fig. 1*




Fig. 2




Fig. 3






Fig. 4






Fig. 7




Fig. 8




Fig. 9




Fig. 10A




Fig. 10B

6/28




Fig. 11




Fig. 12










Fig. 13










Fig. 20




Fig. 21




Fig. 22




Fig. 23




Fig. 24




Fig. 25




Fig. 26A






Fig. 26B






Fig. 27C






Fig. 28






Fig. 31






Fig. 32









Fig. 34





Fig. 35







Fig. 38






Fig. 39

*Fig. 40*









Fig. 42










Fig. 46









Fig. 47





*Fig. 52*

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**